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ABSTRACT 
T CELLS BEARING A CHIMERIC ANTIGEN RECEPTOR AGAINST THE 
TUMOR VASCULATURE DESTROY THE TUMOR ENDOTHELIUM AND 
RESULT IN TUMOR REGRESSION 
Stephen Santoro 
George Coukos, M.D., Ph.D. 
Aberrant blood vessels enable tumor growth, provide a barrier to immune infiltration, and 
serve as a source of pro-tumorigenic signals.  Targeting tumor blood vessels for 
destruction, or tumor vascular disruption therapy, can therefore provide significant 
therapeutic benefit.  Here I describe the development of two chimeric antigen receptors 
(CAR)s against the tumor vasculature, targeting either tumor endothelial marker 1 
(TEM1) or prostate-specific membrane antigen (PSMA).  CAR T cells incorporating 
scFv78, an scFv isolated against TEM1, were able to recognize immobilized plate-bound 
TEM1 protein, but were unable to recognize TEM1 on the surface of endothelial cell 
targets.  In contrast, anti-PSMA CAR T cells, which incorporate the J591 scFv, were able 
to recognize human PSMA (hPSMA) both in vitro and in vivo.  To elucidate the role of 
intracellular signaling domains on endothelial cell killing, a panel of the J591-based CAR 
T cells was characterized, each harboring a different combination of the intracellular 
signaling domains, CD3 zeta (ζ), CD28 (28), and CD137/4-1BB (BB).  I found that all 
anti-hPSMA CAR T cells were able to recognize and eliminate PSMA+ endothelial 
targets in vitro, regardless of signaling domain.  Furthermore, T cells bearing the 3rd 
generation anti-hPSMA CAR, P28BBζ, were able to recognize and kill primary human 
v 
endothelial cells isolated from gynecological cancers.  In addition, the P28BBζ CAR T 
cells were able to mediate regression of hPSMA-expressing vascular neoplasms in mice.  
Finally, in murine ovarian cancers models populated by murine vessels expressing 
hPSMA, the P28BBζ CAR T cells were able to ablate PSMA+ vessels, cause secondary 
depletion of tumor cells, and reduce tumor burden.  Taken together, these results provide 
strong rationale for the use of CAR T cells as agents of tumor vascular disruption, 
specifically those targeting PSMA.  
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CHAPTER 1: INTRODUCTION 
  
2 
The deviant role of blood vessels in tumor development 
The organs of the body depend upon the circulatory system for oxygen and 
nutrient exchange, waste removal, and the distribution of chemical signals as well as 
immune cells.  Tumor development is also dependent upon the vasculature.  In normal 
tissues, the distribution of blood vessels is well organized and structured, allowing for 
even perfusion and nutrient exchange to occur throughout vascularized organs.  In stark 
contrast, tumor vasculature is torturous and unorganized, with microregions within the 
tumor often experiencing hypoxia and nutrient deprivation (Figure 1a–d).  Nonetheless, 
tumors depend on these aberrant vessels for growth and remain dormant until the 
angiogenic switch occurs, a process necessary for tumors to enlarge beyond the diffusive 
limits of oxygen through tissue.1  Physiological angiogenesis is tightly regulated and new 
vessels are only recruited into tissues when the equilibrium between pro-angiogenic and 
anti-angiogenic factors is perturbed, as in the case of wound healing.  This process is 
known as the “angiogenic switch”.  The tumor and associated cells are able to manipulate 
this equilibrium, facilitating vessel formation, by producing pro-angiogenic factors.2 
During the angiogenic switch, normal regulation of vessel development is lost and 
abnormal tumor blood vessels are formed.  The role of these vessels in tumor 
development is not restricted to oxygen and nutrient exchange, however, and the 
endothelial cells lining these vessels also play important and multifaceted roles in 
additional aspects of tumor progression. 
Until recently, the crosstalk between the tumor and the endothelium was largely 
thought to be unidirectional.  Tumor cells, as well as tumor associated cells, were known 
3 
to secrete pro-angiogenic factors, such as members of the vascular endothelial growth 
factor (VEGF) family, enabling tumor vascularization and facilitating nutrient exchange.  
Additional methods by which the endothelium could support tumor growth were 
considerably overlooked.  A deeper understanding of tumor endothelial biology has 
begun to shift this paradigm, however, and the role for endothelial cell signaling in tumor 
development has gained appreciation.  Work from the lab of Lee M. Ellis, for example, 
recently identified the tumor endothelium as a source of angiocrine factors that contribute 
to the stem-ness of nearby cancer cells, thereby promoting both disease severity and 
resistance to chemotherapy.3  Tumor endothelial cells are also able to provide important 
growth signals to the tumor, such as interleukin (IL) 6,4 which promote tumor cell 
proliferation.  Taken together, these observations demonstrate that the tumor endothelium 
not only plays a supportive role in cancer progression, but also actively participates in 
tumor development. 
In addition to directly facilitating tumor cell growth, tumor endothelial cells act as 
a barrier to immune infiltration.  Work from our lab has shown that this may occur 
through at least two different mechanisms.  Firstly, T cell homing and adhesion to vessels 
within the tumor can be interrupted by overexpression of genes related to vascular 
homeostasis and T cell adhesion, such as endothelin B receptor.  The presence of 
endothelin B receptor, a G protein-coupled receptor that signals in response to the 
vasoactive peptides ET1, ET2, and ET3, abrogates the ability of T cells to infiltrate into 
the tumor through down regulation of intracellular adhesion molecule-1 on tumor 
endothelial cells.5  Secondly, we have shown that tumor blood vessels up-regulate FasL 
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in response to prostaglandin, vascular endothelial growth factor A (VEGF-A), and IL-10.   
FasL expression by the tumor endothelium preferentially kills CD8+ T cells while leaving 
T regulatory cells unharmed, thus creating an immunosuppressive tumor 
microenivornment.6  These observations further underscore the importance of the tumor 
vasculature in tumor development and provide rationale for the development of therapies 
targeting these cells.     
As multifaceted and essential contributors to the tumor microenvironment, tumor 
blood vessels are an ideal target for cancer therapy.  Large numbers of tumor cells rely on 
a relatively small number of endothelial cells for oxygen and nutrient exchange, for 
example, and destruction of those endothelial cells can mediate a significant impact on 
the tumor burden.7  In addition, the tumor endothelium is directly accessible to 
circulating lymphocytes, allowing them uninterrupted contact with tumor endothelial 
cells without requiring extravasation.  Finally, tumor endothelial cells are generally 
believed to be more genetically stable than the tumor itself, making them less likely to 
escape therapy through mutation.  Given these considerations, the design of anti-vascular 
therapies has focused on the identification of characteristics and proteins that distinguish 
between normal and aberrant blood vessels.  Fortunately, the tumor vasculature is both 
morphologically and physiologically distinct (Figure 1), allowing for the development of 
novel therapeutic directed against these abnormal endothelial cells.            
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Anti-angiogenic therapy versus vascular disruption 
Since Judah Folkman first proposed the notion of targeting the tumor vasculature 
as a means to treat cancer,8 the idea has been approached using two distinct methods.  
Blood vessels are recruited to the tumor either through angiogenesis, vasculogenesis, or a 
combination of both processes.  Angiogenesis involves the recruitment of endothelial 
cells from adjacent blood vessels, whereas endothelial progenitor cells give rise to de 
novo vessels through the process of vasculogenesis.  Both processes involve the release 
of pro-angiogenic factors, such as basic fibroblast growth factor (bFGF) and VEGF, from 
the tumor microenvironment, thereby highlighting a potential avenue of therapeutic 
intervention.  Therapies targeting either the soluble mediators of angiogenesis, or the 
receptors to which they bind, are referred to as anti-angiogenic therapies, and prevent the 
growth of new vessels.  In contrast, vascular disruption therapy has been developed with 
the aim of specifically destroying the existing vasculature and eliciting catastrophic 
effects on the tumor (Table 1, Figure 2).  Currently, anti-angiogenic agents have had the 
largest impact clinically.  
Of the anti-angiogenic therapies developed, those targeting the VEGF family and 
its receptors are the most numerous.  Inhibitors include VEGF aptamers, soluble VEGF 
receptors (VEGFRs), and tyrosine kinase inhibitors designed to impair VEGFR 
signaling.9  The most notable of these agents, however, is a monoclonal neutralizing 
antibody (Ab) generated against VEGF-A and known as bevacizumab,.  Although 
bevacizumab is available to patients, the addition of the antibody to existing treatment 
regimens has only resulted in a modest progression-free survival advantage for 
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individuals receiving the treatment.10,11  This can likely be explained by a number of 
escape mechanisms employed by the tumor, and includes the use of compensatory pro-
angiogenic signaling pathways, the recruitment of endothelial progenitor cells from the 
bone marrow, and the utilization of vasculogenic mimicry, where tumor cells act 
functionally as endothelial cells.12,13,14  In addition to being resistant to anti-VEGF 
therapy, the tumor may become more aggressive in response to VEGF inhibition.  Mouse 
models of pancreatic15 and breast16 cancer have demonstrated that inhibition of VEGF 
selects for tumor cells that are more metastatic and invasive.  As such, there is room for 
improvement in the field of anti-angiogenic therapy.  Vascular disruption represents a 
potential method by which many of these obstacles may be circumvented, and has 
therefore been investigated correspondingly.    
     
Mechanisms of vascular disruption 
In contrast to anti-angiogenic therapy, the intent of vascular disruption therapy is 
to actively destroy the existing tumor vasculature, with the aim of causing extensive 
necrosis at the center of established tumors.  Currently, there are two primary classes of 
pharmacological vascular disruption agents (VDA)s: the tubulin-depolymerizing VDAs 
and the tubulin independent VDAs.17  Representative agents from both classes, CA4P and 
ASA404, respectively, have demonstrated impressive anti-tumor effects in mouse 
models, but have failed to elicit similar efficacy in human trials.18,19,20  After treatment 
with VDAs, a viable rim of tumor cells often remains at the periphery of the tumor, 
where oxygen and nutrient exchange can occur through neighboring tissues (Figure 2).  
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In part, this may explain why VDAs have been ineffective when used as a single agent in 
clinical trials.  Synergy with other treatment modalities, including radiation, 
chemotherapy, and anti-angiogenic therapy, has been observed (reviewed by Siemann17).  
In addition to tumor cell viability at the tumor periphery, cancer persistence after vascular 
disruption therapy may also be sustained through the regrowth of new vessels derived 
from circulating endothelial progenitor cells recruited to the tumor following treatment.21  
In part to overcome this obstacle, our lab has focused on the development of T cell based 
vascular disruption therapies, as T cells have the potential to persist long term within the 
patient, and may be able to recognize and destroy new tumor endothelial cells as they 
form.   
 Wei et al. were the first to report tumor regression in response to an endothelial 
cell vaccination.22  In this study, the authors found that xenogeneic transfer of primary 
human endothelial cells protected mice from subsequent tumor challenge.  Auto-reactive 
antibodies were recovered from the serum of immunized mice and CD4 T cells were 
found to play a critical role in the anti-tumor response.  In an effort to involve CD8 T 
cells in the anti-tumor vasculature response, work from our lab has focused on the 
development of a DNA vaccine against tumor endothelial marker 1 (TEM1).  Both 
prophylactically and as a treatment, DNA vaccination against TEM1 was shown to 
induce an anti-TEM1 T cell response capable of preventing tumor growth and eliciting 
tumor regression.23  Importantly, epitope spreading played a significant role in the anti-
tumor response, and is a noteworthy advantage to using cell based vascular disruption 
techniques.    
8 
 Anti-tumor vasculature T cells can either be created through vaccination or 
generated using an artificial T cell receptor (TCR) or chimeric antigen receptor (CAR).  
Engineered T cells have a number of significant advantages over T cells elicited in 
response to vaccination.  Central and peripheral tolerance, for example, select against 
high affinity T cell clones that recognize self-antigens.  This is detrimental to the anti-
tumor response, as most tumor antigens are either closely related to normal proteins, or 
are over-expressed self-proteins.  Engineered T cells can bypass this obstacle, as high-
affinity receptors can be isolated and transduced into adoptively transferred T cells.  In 
addition, ex vivo generated T cells can be expanded to large numbers before infusion, 
surpassing the expansion expected from a normal immune response, particularly one 
occurring within the immunosuppressive setting of the tumor microenvironment.  
Therefore, our lab has focused on the development of engineered T cells capable of 
recognizing the tumor vasculature.   
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CHAPTER 2: REDIRECTING T CELLS AGAINST THE 
TUMOR VASCULATURE 
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Introduction 
The process of tumor development is intricately linked to changes in the local 
tumor microenvironment.  In addition to tumor cells, the microenvironment is comprised 
of immune cells, fibroblasts, and aberrant tumor blood vessels, as well as non-cellular 
components such as signaling molecules and the extracellular matrix.  The relationship of 
the tumor with the microenvironment is dynamic, and cross talk between the two 
contributes to cancer progression.6 Within the microenvironment, tumor blood vessels 
play a central role, providing both oxygen and nutrient exchange to the tumor.1 In 
addition, endothelial cells lining the blood vessels (i.e. the endothelium) can provide 
growth signals, such as interleukin (IL) 6,4 which promote tumor cell proliferation.  The 
tumor endothelium can also provide a physical barrier to immune cell infiltration, 
actively protecting the tumor from immunosurveillance.5,6  In addition, tumor endothelial 
cells are able to secrete angiocrine factors that contribute to the stemness of nearby 
cancer cells, promoting both disease severity and resistance to chemotherapy.3 Together 
these findings emphasize the importance of the tumor vasculature in cancer progression 
and indicate that destruction of vessels may have an important impact on tumor 
development.    
Adoptive transfer anti-vasculature T cells is an attractive therapeutic approach for 
vascular disruption, as engineered T cells have the potential to develop into memory T 
cell populations and can persist long-term in patients.24 The persistence of these anti-
vascular T cells will presumably impair the growth of the tumor by continually 
eliminating newly formed tumor vessels. In addition, tumor blood vessels are directly 
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accessible to circulating T lymphocytes.   Furthermore, tumor endothelial cells are 
generally more genetically stable than tumor cells, and thus less able to develop immune 
escape variants.  Finally, adoptively transferred T cells are able to induce epitope-
spreading,25 and possibly generate a de novo T cell response against the tumor and/or the 
tumor vasculature, thereby enhancing the potency of the anti-tumor response.  As such, I 
sought to develop engineered T cells to target the tumor vasculature.  
 
Engineering T cells to recognize the tumor vasculature 
 Adoptive cell-based therapy is defined as the ex vivo expansion and subsequent 
re-administration of autologous T cells into a tumor bearing patient.  This can be 
performed through the expansion of tumor infiltrating lymphocytes (TIL), or by 
engineering T cells to express an exogenous receptor.  The success of TIL therapy in the 
treatment of melanoma has, in large part, validated the use of T cells in cancer therapy.  
Data from three recent clinical trials performed at the NCI, for example, revealed 
objective responses in 52/93 patients treated with TIL therapy.26  Impressively, nearly all 
of the complete responders remained disease free for over 64 months.  Not all patients 
and cancers present with TIL, however, so emphasis has been placed on the generation of 
tumor antigen-specific T cell receptors (TCRs) that can be used to redirect patient T 
cells.27   
 The anti-tumor impact of TCR transduced T cells is also most evident in 
melanoma.  T cells bearing high affinity TCRs against the tumor epitopes, MART-1 and 
gp-100, were able to elicit objective responses in 6/20 and 3/16 patients, respectively.28  
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These results are particularly impressive because the patients enrolled in these trials were 
heavily pretreated using conventional therapies prior to adoptive transfer and all showed 
signs of progressive disease.  Although potent, there are significant disadvantages to TCR 
based ACT.  The most notable of these is the restriction of a given TCR for a single 
MHC haplotype, which is further complicated by the fact that 40–90% of tumors are 
MHC class 1 deficient, as a result of immunoediting.29  It is possible to avoid these 
obstacles, however, using a second class of engineered receptors, referred to as chimeric 
antigen receptors (CARs).    
 
Chimeric antigen receptors 
 A CAR consists of an extracellular single chain variable fragment (scFv) fused to 
an intracellular signaling domain, most commonly the CD3ζ domain derived from the 
TCR complex (Figure 3).  Early trials utilizing 1st generation CAR T cells (CD3ζ 
signaling only) failed to elicit significant anti-tumor responses.  This was attributed to a 
lack of persistence of the CAR-bearing T cells.30,31  Drawing on the knowledge of 
physiological T cell activation, it was predicted that the addition of costimulatory 
domains would increase the longevity and effort function of CAR-bearing T cells and 
thus second generation CARs were created utilizing costimulatory domains such as CD28 
and 4-1BB.  As anticipated, the 2nd generation CAR T cells were found to be superior to 
1st generation CAR T cells in both effort function and persistence.32,33  Finally, 3rd 
generation CARs were constructed using all three intracellular signaling domains (CD28, 
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4-1BB, and CD3ζ) and have been found to function as well as, if not better than 2nd 
generation CAR T cells when administered in vivo.34,35   
The ability of these later generation CAR T cells to elicit profound anti-tumor 
effects in human patients was recently highlighted in the results of a small clinical trial 
for patients with chronic lymphocytic leukemia (CLL). Two of the three patients treated 
with CAR T cells directed against the B cell leukemia marker, CD19, experienced 
complete remission that remained durable for over two years, while the 3rd patient 
experienced a partial response.24,36  In addition to being efficacious against blood-borne 
cancers, there is strong evidence to suggest that CAR T cells directed against the tumor 
vasculature can also elicit significant effects against solid tumors.  For example, murine 
CARs directed against VEGFR-237 or VEGFR-1 and VEGFR-238 were effective in 
suppressing tumor growth in mice challenged with various tumors.  However, these 
targets are also expressed by normal endothelial cells throughout the body, and therefore 
represent a risk for “on-target/off-tumor” toxicity.  I therefore sought to develop CAR T 
cells capable of recognizing alternative tumor vascular antigens with more favorable 
expression profiles within normal tissues.        
 
Identifying targetable tumor vascular antigens 
 The tumor vasculature is morphologically and physiologically distinct from the 
normal vasculature.  Numerous surface proteins have been identified that are either 
upregulated or present exclusively on the vessels of the tumor.39,40  Given their known 
role in angiogenesis, the VEGFRs were quickly identified as upregulated surface 
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receptors present more abundantly on the tumor vasculature than normal vessels.41  
VEGFR-1 and VEGFR-2 are also expressed by normal vessels throughout the body, 
however, making them suboptimal targets for vascular disruption therapy.42  As such, the 
field has focused on the identification of unique tumor vascular antigens, which 
demonstrate a more restricted expression profile.   
 To identify novel tumor vascular targets, quantifiable gene expression assays, 
such as serial gene analysis (SAGE), have been used to detect genes that are present on 
the tumor endothelium but absent on the normal vasculature.  By comparing the mRNA 
transcription profiles of endothelial cells isolated from colon tumors with that of normal 
colon endothelial cells, St. Croix et al. were able to identify 46 tumor endothelial markers 
expressed at least 10 fold higher by the tumor endothelium.40  The transcript most 
abundantly expressed by the tumor endothelium was termed TEM1.  Additional studies 
have confirmed TEM1 over-expression on the vasculature of a variety of human 
cancers,43,44 including ovarian carcinoma.39,44 In contrast, TEM1 expression appears to be 
restricted on normal adult tissues.45,46  Although a functional role for TEM1 has not been 
completely elucidated, over-expression of the protein has been shown to correlate with 
disease severity and recurrence in breast cancer.43  This is further supported by the 
observation that TEM1 knock out (TEM1–/–) mice show resistance to tumor 
development.47  Importantly, the TEM1–/– mice are otherwise healthy and do not display 
complications in wound healing or angiogenesis, suggesting that therapies directed 
against TEM1 will elicit significant anti-tumor effects with minimal toxicity.  This 
assertion is further supported by the recent work of Facciponte et al, who showed that 
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vaccination against TEM1 was able to elicit a strong anti-tumor response, without 
observable toxicity or impairment in either wound healing or reproductive health.23 
Taken together, these data suggest that TEM1 would be an ideal target for CAR based 
vascular disruption therapy due to its favorable expression profile and implication in 
tumorigenesis.   
 Alternative tumor vascular antigens have also been identified.  One such example 
is prostate-specific membrane antigen (PSMA), a type II membrane protein of the M28 
peptidase family that is also known as glutamate carboxypeptidase II (GCPII) or folate 
hydrolase 1 (FOLH1).  While validating an antibody against the extracellular region of 
PSMA, Liu et al. identified expression of the protein on the vasculature of a panel of 
solid tumors.48  This observation was confirmed by others, and expanded to include a 
wide variety of solid tumors (summarized in Table 2).49,50,51 While PSMA is absent on 
the normal endothelium, it has been detected on a subset of normal adult tissues.52  
Antibody therapies directed against PSMA have been largely free of toxicity,53 however, 
suggesting that T cell based therapies targeting PSMA will also have a favorable safety 
profile (reviewed in Chapter 3 and discussed in Chapter 4).  Thus, there is also strong 
rationale for the development of anti-vascular CAR T cells directed against PSMA.     
 
Tumor endothelial marker 1 
 TEM1 (CD248 or endosialin) is a 757 amino acid type I membrane bound protein, 
which consists of a large extracellular domain C-type lectin domain, a Sushi/CCP/scr 
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domain, and 3 EGF repeats.54  Initially identified by immunohistochemical staining of 
tumors sections stained with a mouse monoclonal antibody (m)Ab isolated from mice 
inoculated with human fetal fibroblasts, TEM1 was observed on the tumor vasculature.55  
In mice, TEM1 is expressed during embryonic development, but has a limited expression 
profile in adult animals, making it an attractive target for vascular disruption therapy.56  
Furthermore, TEM1 has been implicated in tumor progression, as TEM1–/– mice 
demonstrate impaired tumor growth, but are otherwise developmentally normal.47  Given 
these characteristics, I sought to develop CAR T cells that would recognize TEM1. 
 
Development of a CAR to target TEM1 
 Utilizing a yeast display library generated from a patient with thrombotic 
thrombocytopenic purpura, Zhao et al. isolated 5 scFv fragments capable of recognizing 
the extracellular portion of TEM1.57  The binding potential of these scFvs varied, with 
scfv78 exhibiting the highest affinity (Table 3).  I cloned each of the five scFvs (78, 131, 
132, 133, and 137) into a series of self-inactivating lentiviral cassettes (Figure 4a), which 
utilize 3rd generation safety features.58  From these vectors, CAR expression was driven 
by the EF-1α promoter.  All constructs contained an eGFP reporter and the CD3ζ 
intracellular signaling domain.  Primary human T cells were transduced with lentivirus 
generated from these constructs, and transduction efficiency was monitored by eGFP, 
which was detected by flow cytometry (Figure 4b).  To test whether the eGFP reporter 
accurately reflected CAR surface expression in transduced T cells, I stained scFv78 CAR 
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T cells with a goat anti-rabbit F(ab)2 fragment.  Surface expression correlated highly with 
eGFP expression, validating the use of the eGFP reporter in these cells (Figure 4c).    
 Next, I sought to evaluate the ability of the anti-TEM1 T cells to recognize 
immobilized TEM1 protein.  The anti-TEM1 CAR T cells were cultured in wells coated 
with either recombinant human TEM1 (hTEM1) protein or BSA as an irrelevant protein 
control.  An IFN-γ ELISA was performed on the supernatants collected from the wells 
after overnight co-culture and I found that T cells bearing the scFv78 CAR were able to 
recognize the plate-bound hTEM1 protein (Figure 5a).  In contrast, T cells harboring any 
of the lower affinity CARs were unable to recognize the plate bound protein, suggesting 
that the affinity of these scFvs may not be sufficient to confer recognition and activation 
to the CAR T cells (Table 3).  scFv78 is capable of recognizing both human and murine 
TEM1 (mTEM1).57  To test whether the 78ζ CAR T cells could recognize mouse and/or 
human TEM1 on the surface of endothelial cells, I performed overnight co-cultures of the 
78ζ CAR T cells with either the 2H11 cell line, which has been shown to express murine 
TEM1,57 or the MS1TEM1 cell line which I had previously engineered to express human 
TEM1 (Figure 5b).  Surprisingly, I found that the 78ζ CAR T cells were unable to 
recognize either murine or human TEM1 when expressed on the surface of endothelial 
cells (Figure 5c).  T cells bearing a CAR against mesothelin (P4ζ) were used as a 
specificity control in this experiment, and reacted exclusively against the ovarian cancer 
cell line A1847, which is known to express mesothelin.59 
 One potential explanation as to why the 78ζ CAR T cells could recognize 
immobilized TEM1 protein, but not TEM1 expressed on the cell surface, is that the hinge 
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domain connecting scFv78 to the transmembrane region of the CAR may not extend 
sufficiently from the T cell surface to allow epitope recognition.  This is supported by the 
observation that the soluble form of scFv78 could be used to detect TEM1 on endothelial 
cells (see Figure 5b).  Furthermore, others have shown that the extension of an scFv 
from the surface of a CAR T cell can influence the T cell’s ability to recognize its target 
antigen.60  Therefore, I cloned scFv78 into a CAR construct containing the IgG4 hinge, 
rather than the CD8α hinge.  The CD8α hinge domain, isolated from the TCR complex, is 
45 amino acids in length.  In contrast, the IgG4 hinge is 231 amino acids (Figure 6a), and 
extends further from the T cell surface than the CD8α hinge domain (Figure 6b).  CAR T 
cells bearing one of the two hinge domains were cultured with endothelial targets 
expressing hTEM1, and IFN-γ was measured in supernatants collected after overnight co-
culture.   I did not detect IFN-γ production from either set of anti-TEM1 CAR-bearing T 
cells, regardless of hinge domain, nor did I detect killing of the target cell lines, as 
measured by luciferase killing assay (Figure 6c,d).  T cells bearing a CAR against human 
folate receptor α (FR), were used as a specificity control throughout these experiments, 
and were found to react solely against targets engineered to express folate receptor.  
These data suggest that the epitope recognized by scFv78 may be deeply hidden within 
the proteins of the surface membrane and also demonstrate that extension of the hinge 
domain of the scFv78 CAR, using the IgG4 hinge, will not overcome this obstacle.   
 Recent work from the Powell lab has demonstrated that T cells bearing a biotin-
binding immune receptor (BBIR) can react against targets labeled with biotinylated 
antibody (Figure 7a).61   Since I observed that the soluble form of scFv78 was able to 
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label TEM1+ cells (Figure 5b), I hypothesized that BBIR T cells may be able to 
recognize TEM1+ endothelial labeled with biotinylated scFv78.   To begin, I biotinylated 
scFv78, as well as two additional antibodies known to bind TEM1 (K16 and 
MORAb004), using a commercially available biotinylation kit.  To confirm successful 
biotinylation, the MS1 and MS1TEM1 endothelial cells were stained using the biotinylated 
anti-TEM1 antibodies (Figure 7b).  Surprisingly, co-culture of the BBIR T cells with the 
labeled target cells did not result in recognition of the MS1TEM1 endothelial cells, 
regardless of the antibody or scFv used (Figure 7c).  Taken together, these results further 
suggest that developing CAR T cells capable of recognizing TEM1 may be difficult using 
the currently available antibodies and scFvs.  
 
Prostate-specific membrane antigen 
 Prostate-specific membrane antigen (PSMA) is a 750 amino acid type II 
membrane bound protein.  Contrary to its name, PSMA is also expressed in the 
neovasculature of a wide variety of solid tumors (see Table 2), making it a potential 
target for CAR mediated endothelial cell killing.  The PSMA locus encodes a number of 
splice variants, including multiple membrane-bound and cytosolic isoforms of the 
protein,62,63 and the ratio of membrane to cytosolic PSMA was shown to be higher in 
prostate cancer cells when compared to the normal prostate.64  Recent studies have 
demonstrated that the surface expression of PSMA confers a proliferative advantage to 
tumor cells through its function as a hydrolase of poly- and gamma-glutamated folate.65  
In addition, PSMA is known to function as a N-acetylated α-linked acidic dipeptidase 
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(NAALADase) of the neuropeptide NAAG in the brain.66  As such, it is presumed that 
PSMA plays a metabolic role on the activated tumor endothelium.  However, additional 
functions have also been ascribed to PSMA.  PSMA was shown to be important in 
endothelial cell invasion, for example, and mice lacking PSMA exhibit impaired 
angiogenesis.67  Furthermore, expression of PSMA by the LNCaP prostate cancer cell 
line has been shown to induce the expression and secretion of interleukin (IL) 6, which 
increases the proliferative potential of the tumor cells.68  Since the tumor endothelium has 
also been shown to be an important source of IL-6,4 it is conceivable that PSMA 
signaling is also involved in the production of IL-6 from these cells as well.  Taken 
together, these data describe PSMA as a tumor endothelial marker, and also implicate the 
protein in tumor progression.  As such, there is strong rationale to pursue the 
development of CAR T cells to target the endothelial cells that express PSMA.      
 
The design and characterization of a CAR against PSMA 
Research from the laboratory of Michel Sadelain has shown that CAR T cells 
targeted against hPSMA (hereafter referred to as PSMA) are able to eliminate prostate 
cancer cells in vitro as well as in vivo.35 The scFv utilized in these constructs was derived 
from the mouse mAb J591, which was also used to identify PSMA on blood vessels 
within a number of solid tumors.48,49,50 I therefore utilized the J591 scFv in the design of 
my CAR constructs, which I referred to as Pζ, P28ζ, PBBζ, and P28BBζ based upon the 
intracellular signaling domain incorporated into their design.  In addition, I also utilized a 
specificity control CAR, FR28BBζ, which recognized the non-vascular antigen, human 
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folate receptor alpha (FRα).69  Each CAR was subcloned downstream of an eGFP 
reporter within the pELNS lentiviral cassette (Figure 8a,b). Transduction efficiencies 
ranged from 50–90% in primary human T cells (Figure 8c).  To confirm CAR surface 
expression, the P28BBζ T cells were stained with a goat anti-mouse F(ab)2 fragment.  
eGFP expression and CAR surface detection were strongly correlated, validating the use 
of the eGFP reporter as a proxy for CAR expression (Figure 9).  
The effector function and persistence of CAR-bearing T cells is dependent upon 
the signaling domains incorporated in their design.  Co-stimulation through CD28 and/or 
4-1BB augments CAR T cell function, generating a more potent anti-tumor response.34,35 
Although this has been described in the context of tumor cell killing, there is a paucity of 
data defining the role of co-stimulation in endothelial cell destruction.  Therefore, I 
compared the ability of my anti-PSMA CAR T cells, containing the ζ, 28ζ, BBζ, or 
28BBζ signaling domains, to function against endothelial targets in vitro.   
Although PSMA is present on the tumor endothelium in vivo, it has not been 
described on endothelial cells in culture.  To ascertain whether cultured human 
endothelial cells express PSMA, I stained both the immortalized HMEC-1 cell line70 as 
well as primary human umbilical vein endothelial cells (HUVEC), using the J591 mAb.  I 
was unable to detect PSMA on either the HMEC-1 (see Figure 11a, top row) or the 
HUVEC (not shown).  I therefore engineered the HMEC-1 to express PSMA isoform 1, 
using lentivirus (see Figure 11a, bottom row).  To compare the ability of the different 
CARs to redirect T cells towards endothelial PSMA, I first measured the proliferative 
capacity of the CAR bearing T cells in response to the HMEC-1PSMA cell line.  All CAR 
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T cells, regardless of their signaling domain, proliferated in response to the HMEC-1PSMA 
(Figure 8d,e), but did not proliferate in response to the antigen negative HMEC-1 (not 
shown).  There were no statistical differences between the groups.  Control FR28BBζ 
CAR T cells did not show any significant proliferation in response to the HMEC-1PSMA 
when compared to untransduced T cells (Figure 8e).  Similarly, I observed that all the 
anti-PSMA CAR T cells were able to specifically kill the HMEC-1PSMA during overnight 
co-culture, with no significant differences detected between the anti-PSMA T cells, 
regardless of signaling domain (Figure 8f).  Finally, I compared the ability of each CAR 
to confer resistance to apoptosis by measuring the anti-apoptotic factor, Bcl-xL, after 
activation.  After co-culture with the HMEC-1PSMA, the P28BBζ T cells induced the 
highest levels of Bcl-xL expression, although this observation did not reach statistical 
significance (Figure 10).  Interestingly, in the context of tumor cell targeting, the impact 
of the different CAR signaling domains was found to be less evident in vitro and more 
pronounced in vivo.34  In this setting, third generation CAR T cells (28BBζ) were found 
to be equivalent or superior to either 1st (ζ) or 2nd (28ζ or BBζ) generation CAR T 
cells.34,35 Thus, I selected the P28BBζ T cells for further experimentation (Chapter 3). 
 
Conclusions 
 TEM1, although an attractive tumor vascular marker, has been difficult to target 
using currently available CAR T cells.  Of the 5 anti-TEM1 scFvs isolated by Zhao et 
al.,57 only T cells bearing the scFv78-based CAR were able to recognize immobilized 
plate bound TEM1 protein.  Unfortunately, this recognition did not correspond to a 
23 
commensurate recognition of TEM1 on the surface of endothelial cell lines (Figure 5).  I 
hypothesized that the binding epitope for scFv78 may be embedded within the proteins of 
the endothelial cell surface, and that hinge extension could liberate the scFv sufficiently 
to allow recognition and T cell activation.  Co-culture of T cells bearing an extended 
hinge domain, however, failed to recognize TEM1 when expressed on the surface of 
targeted cell lines (Figure 6).  Finally, I utilized a “universal” CAR T cell approach, 
where TEM1+ targets were labeled with biotinylated scFv78 and co-cultured with T cells 
bearing a streptavidin-based BBIR.  Although staining with scFv78 was confirmed by 
flow cytometry, the BBIR T cells failed to recognize the labeled targets (Figure 7).  
Taken together, these data suggest that the binding epitope for scFv78 is masked in such 
a way that given these current CAR designs, it cannot be recognized.  Further study 
should be directed towards the development of CAR T cells with more flexible hinge 
domains and also the isolation of novel anti-TEM1 scFvs that may bind a more accessible 
region of the TEM1 protein.   
 In contrast, I also demonstrated that T cells bearing J591-based CARs were able 
to successfully recognize and eliminate human endothelial cells engineered to express 
PSMA.  In vitro, I noted that anti-PSMA CAR T cells were able to proliferate in response 
to antigen, and successfully eliminate PSMA+ targets, regardless of the signaling domains 
incorporated into their design.  Further study would be needed to extend these 
observations in vivo, but I expect that the differences between the signaling domains will 
become more apparent, as has been demonstrated for tumor targeting CAR T cells.34,35  
Importantly, this work establishes that T cells bearing J591-based CARs can recognize 
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PSMA on the surface of endothelial cells, and activate in response to the antigen.  The 
anti-PSMA CAR T cells identified in this work were subsequently used to interrogate the 
effects of T cell-mediated vascular disruption, which is described in Chapter 3.    
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CHAPTER 3: T CELLS BEARING A CHIMERIC ANTIGEN 
RECEPTOR AGAINST PSMA MEDIATE VASCULAR 
DISRUPTION AND RESULT IN TUMOR REGRESSION 
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Introduction 
Vascular disruption has the potential to mediate profound anti-tumor effects, as 
evidenced by murine tumor models (Figure 2).18,20   The impact of utilizing T cells to 
elicit vascular disruption, however, is less well established.  Recent work targeting 
VEGFR2 has demonstrated that CAR T cells can destroy the tumor endothelium and that 
vascular disruption impairs tumor growth.37  I aimed to build upon this observation and 
demonstrate that targeting the tumor vasculature with CAR T cells against PSMA can 
cause tumor cell death and subsequent tumor regression.   
Here, I demonstrate that 3rd generation CAR T cells, containing the 28BBζ 
signaling domain, efficiently and specifically target human and mouse endothelial cells 
expressing the PSMA in vitro, as well as eliminate murine hemangioma and 
hemangiosarcoma tumors expressing PSMA in vivo.  I also demonstrate the P28BBζ T 
cells can ablate PSMA+ tumor vessels within two ovarian tumor models populated with 
murine endothelial cells transduced to express PSMA, and that elimination of these 
vessels results in secondary depletion of tumor cells and reduced tumor burden.  Overall 
this work demonstrates for the first time that PSMA is a valid target for CAR T cell-
mediated tumor blood vessel destruction, and highlights the viability of the approach as 
an effective anti-cancer therapy.   
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P28BBζ T cells recognize and eliminate PSMA-positive endothelial cells 
in vitro 
To begin, I engineered human PSMA expression on the surface of the 
immortalized human endothelial cell line, HMEC-1, as well as the surface of two mouse 
endothelial cell lines, the immortalized MS1 line as well as the H5V angiosarcoma line 
(Figure 11a).  To assess the specificity and ability of the P28BBζ T cells to react against 
these endothelial targets, I performed IFN-γ ELISA on supernatants collected after 
overnight co-culture of the CAR T cells with the PSMA-negative human (HMEC-1) or 
mouse (MS1, H5V) endothelial cell lines and their PSMA-transduced counterparts 
(HMEC-1PSMA, MS1PSMA, H5VPSMA).  I found that IFN-γ production by the P28BBζ CAR 
T cells was limited to the cultures containing the PSMA+ endothelial cells (Figure 11b).  
Next, I asked whether the P28BBζ CAR T cells would be able to specifically kill the 
PSMA+ endothelial cells.  Using a chromium release assay, I found that the P28BBζ CAR 
T cells eliminated the majority of the PSMA+ endothelial cells within 18 h of co-culture, 
while the PSMA– cell lines were largely unaffected (Figure 11c).  
 
PSMA is expressed on the vasculature of primary and metastatic cancer 
PSMA has been detected on tumor blood vessels in a variety of cancers, including 
ovarian51 (summarized in Table 2). To confirm this observation I performed 
immunohistochemistry on a tissue microarray (TMA) comprised of 13 primary ovarian 
cancer specimens and 15 matched metastases (Figure 12a, top row).  I observed PSMA 
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expression on vessel-like structures within the majority of tumors, with 12/13 (85%) of 
the subjects expressing PSMA within their primary ovarian lesion(s), and 14/15 (93%) 
expressing PSMA on one or more of their metastases (Figure 12b).  I did not identify 
PSMA on any of the 16 normal ovary cores analyzed.  Endothelial expression of PSMA 
was confirmed by co-staining of the TMA using a CD34 antibody in addition to the anti-
PSMA antibody (Figure 12a, bottom row).  Here I noticed the presence of CD34+PSMA– 
vessels in some of the cores analyzed (Figure 12c), corroborating observations made in 
other cancer types where PSMA expression was noted to be heterogeneous on vessels 
within the tumor (Table 4).  To define the percentage of endothelial cells expressing 
PSMA within the tumor, I examined freshly dissociated cancer samples by flow 
cytometry.  In support of my observations by IHC, I found PSMA expression on 
approximately 40–60% of the CD45–CD31+ endothelial cells (Figure 12d). 
Next I asked whether the P28BBζ CAR T cells were capable of recognizing and 
killing tumor endothelial cells isolated from individuals with cancer.  Tumor endothelial 
cells were enriched from freshly dissociated tumor samples first by negative selection of 
CD45+ leukocytes and then by positive selection of CD31+ endothelial cells using 
magnetic bead sorting.  CD31-enriched and CD31-depleted tumor-derived cells were 
then incubated with P28BBζ CAR T cells for 18 h.  I found that the P28BBζ CAR T cells 
substantially reduced the percentage of PSMA+ endothelial (CD45–CD31+) cells in the 
primary tumor-derived cells.  The control FR28BBζ CAR T cells had no impact on the 
percentage of PSMA+ cells remaining in the culture (Figure 12e).  To confirm the 
activation of the P28BBζ CAR T cells in these cultures, I performed IFN-γ ELISA on the 
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supernatants collected from the overnight co-cultures of the P28BBζ CAR T cells with 
either the CD31-enriched or the CD31-depleted populations.  IFN-γ was produced in all 
instances where the P28BBζ T cells were co-cultured with the CD31-enriched endothelial 
cells (Figure 12f).  Interestingly, I also observed IFN-γ production in one of the CD31-
depleted co-cultures (Figure 12f, #1913).  To determine whether expression of PSMA by 
the tumor cells could explain this observation, I stained the CD45–CD31– population for 
PSMA as well as FRα, a tumor-specific antigen in ovarian cancer.71 For subject #1913, I 
found that a substantial portion of the FRα+ cells stained positive for PSMA (Figure 
13a).  Because the main cell populations in the CD45–CD31– fraction are tumor cells and 
stroma fibroblasts, and because the stroma of gynecologic cancers does not express the 
FRα,72,73 these findings suggest that tumor cells for some individuals with ovarian cancer 
may also express PSMA, which has been noted for other cancers.52 Collectively, this 
data, along with numerous published reports (Table 2), demonstrate that PSMA is widely 
expressed in the tumor vasculature and provide rationale for the development of CAR T 
cell therapy against this antigen. 
 
P28BBζ CAR T cells target human tumor vasculature expressing PSMA 
To simulate the interactions of P28BBζ CAR T cells with human tumor blood 
vessels in vitro, I plated HMEC-1 or HMEC-1PSMA endothelial cells on Matrigel 
basement membranes and allowed the cells to self-assemble into microvessels (8 h).  
Upon assembly, T cells were added, and the cultures were monitored for 48 h by 
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fluorescence microscopy (Figure 14a).  As early as 24 h after addition of the T cells to 
the microvessels, I observed specific localization of the P28BBζ CAR T cells with the 
HMEC-1PSMA microvessels.  Within 48 h, the HMEC-1PSMA vessels were destroyed 
(Figure 14b).  In contrast, the antigen-negative microvessels persisted throughout the 
duration of the co-culture with the P28BBζ CAR T cells.  As expected, the control 
FR28BBζ CAR T cells, directed against the FRα, did not impact the persistence of either 
the HMEC-1 or HMEC-1PSMA microvessels.  These data indicate that the P28BBζ CAR T 
cells were able to specifically recognize PSMA+ vessels, but not the normal (PSMA–) 
vascular structures, in vitro. 
I next assessed the ability of the P28BBζ CAR T cells to recognize human 
endothelial cells expressing PSMA in vivo.  I transplanted Matrigel plugs containing 
either HMEC-1 (left flank) or HMEC-1PSMA (right flank) into severely immunodeficient 
NSG mice (Figure 15a). Immediately after transplantation of the Matrigel plugs, mice 
were given an intravenous (i.v.) injection of either P28BBζ CAR T cells or control 
FR28BBζ CAR T cells.  The plugs and spleens were harvested 11 days after inoculation 
and analyzed for the presence of CAR-positive T cells via flow cytometry.  In mice 
receiving the P28BBζ T cells, I found large numbers of CAR T cells in the plugs 
containing the HMEC-1PSMA cells, whereas the plugs containing control HMEC-1 cells 
were largely devoid of T cells (Figure 15b,c).  Similarly, very few FR28BBζ control T 
cells were found in the plugs containing either the PSMA positive or negative endothelial 
cell lines.  Finally, I measured the percentage of CAR T cells found in the spleens of the 
treated mice and found substantially more P28BBζ CAR T cells compared to mice that 
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received the FR28BBζ control T cells (Figure 15d).  Together, these data demonstrate 
that the P28BBζ CAR T cells are able to recognize and accumulate on PSMA+ 
endothelial cells, and that they are able to persist in vivo in the presence of the antigen. 
 
P28BBζ T cells eliminate PSMA+ vascular neoplasms 
Because the HMEC-1 model did not reproducibly form vascular structures in 
vivo, I used two well-established murine endothelial models, the MS1 hemangioma74 
model and the H5V hemangiosarcoma75 model, to test the therapeutic efficacy of the 
P28BBζ CAR T cells.  First, NSG mice were injected subcutaneously (s.c.) with MS1 
cells (left flank) and MS1PSMA cells (right flank), both of which had been previously 
engineered to express firefly luciferase to allow for non-invasive, real time tumor 
measurement throughout tumor progression and treatment.  Mice were treated with a 
single i.v. administration of 5.0×106 CAR T cells 24 days after tumor inoculation (Figure 
16a). In mice receiving the P28BBζ CAR T cells, I observed rapid regression of the 
MS1PSMA hemangiomas, whereas the antigen-negative MS1 flank was unaffected (Figure 
16b).  Macroscopic examination of the hemangiomas upon sacrifice revealed that 
injection of the P28BBζ CAR T cells led to complete regression of the PSMA+ tumors 
(Figure 16c).  The control FR28BBζ CAR T cells had no impact on either of the 
hemangiomas.  I also tested the P28BBζ T cells against larger, more developed MS1 and 
MS1PSMA hemangiomas (Figure 17a).  Here too, I observed rapid regression of the 
MS1PSMA tumors after administration of the P28BBζ CAR T cells, as measured by both 
luciferase luminescence and caliper measurement (Figure 17b), which I confirmed 
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visually upon sacrifice of the mice (Figure 17c).  Importantly, in both treatment models 
the P28BBζ CAR T cells demonstrated specificity and reactivity exclusively against the 
PSMA+ tumors.  
 Finally, I assessed the ability of the P28BBζ CAR T cells to treat murine H5V 
hemangiosarcoma, an aggressive vascular target that metastasizes to the lung.  Twenty-
one days following i.v. inoculation with H5VPSMA endothelial cells, NSG mice were 
given three i.v. injections of 5.0×106 CAR T cells 72 h apart (Figure 18a).  I monitored 
the progression and response of the tumors to treatment by luciferase luminescence, and 
mice were sacrificed upon losing 10% of their initial body mass.  By the third injection of 
CAR T cells, the H5VPSMA cells were nearly undetectable in the P28BBζ CAR treatment 
group, whereas no effect was seen in the FR28BBζ CAR treatment group (Figure 18b,c).  
Furthermore, mice treated with the P28BBζ CAR T cells lived significantly longer than 
those treated with PBS or FR28BBζ T cells (Figure 18d).  Collectively, these models 
demonstrate that the P28BBζ CAR T cells are able to traffic to and eliminate aberrant 
PSMA+ tumor vessels in vivo, and that PSMA-targeting CAR T cells are potent mediators 
of tumor vascular disruption 
 
CAR T cells ablate PSMA+ vasculature in solid tumors 
Elimination of tumor vessels by vascular disrupting agents can result in the 
regression of solid tumors.76 To test whether P28BBζ CAR T cells could elicit a similar 
effect, I developed a syngeneic vasculature/tumor chimeric transplant model.  Briefly, 
MS1 (or MS1PSMA) murine endothelial cells were co-injected with either murine ID8 
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ovarian tumor cells or ID8VEGF ovarian tumor cells, which were engineered to 
overexpress mouse VEGF164.77  The endothelial and tumor cells were combined at an 
optimal ratio such that the majority of tumor blood vessels would be derived from the 
MS1/MS1PSMA endothelial cells.78,79,80 Figure 19a illustrates a representative experiment 
where mice were inoculated with ID8VEGF, MS1/ID8VEGF, or MS1PSMA/ID8VEGF tumors.  
By day 41, the majority of the CD31+ endothelial cells taken from the ID8VEGF/MS1PSMA 
tumors were found to express PSMA by immunofluorescence microscopy, confirming 
that the exogenous MS1 endothelial cells were substantially contributing to the tumor 
vasculature in this model (Figure 19b). These results were verified by flow cytometry 
analysis, which showed that upwards of 65% of CD31+ endothelial cells purified from 
tumors were PSMA+ (Figure 19c).  Importantly, the CD31+ endothelial cells contributed 
less than 2% to the total cells isolated from the chimeric tumors, which was similar to 
what was observed for the more ID8VEGF-only tumors, in which the vasculature was 
derived from endogenous endothelial cells. As such, I concluded that majority of the 
tumor was derived form the ID8VEGF cells or stromal cells and not the co-injected MS1 
endothelial cells (Figure 19d).  In addition, we noted no difference in the tumor growth 
kinetic between the ID8VEGF and ID8VEGF tumors enriched with MS1 or MS1PSMA cells 
(Figure 19e), further demonstrating that the chimeric tumors reproduced a “normal” 
tumor growth condition, and also confirming that the addition of the MS1 or MS1PSMA 
cells did not substantially contribute to the volume of these tumors. 
I next asked whether the proportion of MS1-derived vessels was consistent 
throughout tumor development.  For these experiments I used MS1 and MS1PSMA cells 
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engineered to express firefly luciferase and ID8VEGF tumor cells engineered to express 
eGFP.  In mice injected with either MS1/ID8VEGF or MS1PSMA/ID8VEGF tumors, I 
compared seven longitudinal luciferase luminescence measurements, obtained between 
day 17 and 41, to seven longitudinal eGFP radiant efficiency measurements obtained at 
the same time points (Figure 20a–e).  I performed linear regression analyses on the 
values obtained and found that endothelial luminescence was strongly correlated with 
tumor fluorescent radiant efficiency (Figure 20a–e), indicating that the exogenous 
endothelial cells expanded proportionally to the tumor cells.  Thus, I concluded that 
within this tumor model the exogenous endothelial cells provided the main source of 
tumor endothelial cells required for neovascular formation.  This data taken together 
indicates that the presence of the MS1 or MS1PSMA vessels largely obviated the need for 
endogenous endothelial cell recruitment, and also shows that the MS1 endothelial cells 
do not constitute a significant portion of the cells within the tumor, supporting the 
assertion that the MS1 cells are predominantly forming tumor blood vessels and not 
contributing substantially to the overall tumor mass.  Finally, I observed that the MS1 and 
MS1PSMA endothelial cells could be followed non-invasively during tumor growth within 
this model, allowing for their persistence or elimination to be monitored after treatment 
with CAR T cells. 
To  test the ability of the P28BBζ CAR T cells to ablate the tumor vasculature in 
vivo, I first utilized  the MS1/ID8 tumor model.  NSG mice were injected with MS1/ID8 
(left flank) and MS1PSMA/ID8 (right flank) tumors, which were allowed to develop for 81 
days before treatment with a single injection of 1.0×107 CAR T cells (Figure 21a).  I 
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found that the P28BBζ CAR T cells were able to quickly eliminate the MS1PSMA 
endothelial cells, as indicated by luciferase luminescence measurements (Figure 21b, 
lower panel).  In contrast, vessels within the MS1/ID8 tumors were unaffected by the 
P28BBζ CAR T cells (Figure 21b, upper panel).  Administration of the FR28BBζ CAR 
T cells had no impact on the tumor blood vessels, confirming the specificity of the 
P28BBζ T cells. 
Since VEGF plays an important role in the development and stabilization of new 
tumor vessels, and has been implicated in tumor resistance to VDAs,81 I next sought to 
evaluate the in vivo impact of the P28BBζ CAR T cells on the vasculature of solid tumors 
expressing high levels of VEGF-A using the ID8VEGF model.77 The MS1/ID8VEGF tumors 
grew more rapidly than the MS1/ID8 tumors, necessitating that the mice be sacrificed 
within approximately 40 days to avoid ulceration.  Mice were therefore treated earlier and 
with three injections of 5.0×106 CAR T cells, beginning 25 days after tumor inoculation 
(Figure 22a).  P28BBζ CAR T cells induced rapid regression of the PSMA+ MS1 
endothelial cell mass but had no effect on control MS1 cells (Figure 22b). In addition, 
the control FR28BBζ CAR T cells had no impact on the blood vessels of either tumor.  
Upon sacrifice I collected and enzymatically dissociated all tumors, which were 
subsequently stained using antibodies for CD31 and PSMA and analyzed via flow 
cytometry.  No CD31+PSMA+ endothelial cells were found within the tumors of the 
P28BBζ-treated mice.  In control treated mice, between 6080% of the CD31+ endothelial 
cells were PSMA+ within the MS1PSMA/ID8VEGF tumors (Figure 22c).  These findings 
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indicate that, like VDAs, CAR T cells can trigger regression of established tumor 
vasculature. 
 
CAR T cells induce secondary loss of tumor cells and regression of solid 
tumors 
To assess whether vascular disruption was causing the secondary loss of tumor 
cells, I examined the effects of P28BBζ CAR T cells on tumor growth in the experiments 
described above.  In the MS1/ID8 model (experiment outlined in Figure 21a), treatment 
with P28BBζ CAR T cells led to a significant decrease in the overall size of the 
MS1PSMA/ID8 tumors,, but not of the antigen-negative MS1/ID8 tumors (Figure 23a).  In 
addition, growth of MS1PSMA/ID8VEGF tumors was significantly impaired in P28BBζ 
treated mice (Figure 24a,b). This response was noted to be dose-sensitive, as mice 
treated with a single injection of 1×107 CAR T cells did not eliminate PSMA+ endothelial 
cells as rapidly and did not inhibit the growth of ID8VEGF tumors as effectively as mice 
treated with three injections of 5×107 CAR T cells.  These data demonstrate that even in 
the context of VEGF overexpression, elimination of the antigen-positive vasculature by 
CAR T cells can lead to significant tumor regression. 
Given that endothelial cells account for less than 2% of the cells found within the 
MS1/ID8VEGF and MS1PSMA/ID8VEGF tumors (see Figure 20d), I hypothesized that the 
regression I observed in the P28BBζ-treated mice was not merely reflecting the loss of 
the MS1PSMA cells from the ID8VEGF tumors, but rather indicating a significant loss of 
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tumor cells in response to T cell mediated vascular disruption.  To ascertain whether this 
was true, I developed an ID8VEGF model in which the tumor cells expressed firefly 
luciferase, while MS1 cells did not.  As before, NSG mice were inoculated with 
MS1/ID8VEGF (left flank) and MS1PSMA/ID8VEGF (right flank) tumors.  Three 
administrations of 5.0×107 CAR T cells were given, beginning on day 22 (Figure 25a).  
Both luciferase luminescence, as well as tumor volume measurements revealed that 
treatment with the P28BBζ T cells impaired tumor growth (Figure 25b).  To determine if 
the P28BBζ T cells were mediating tumor cell destruction, I compared the fold change in 
tumor cell luminescence in mice receiving the P28BBζ T cells.  I observed a significant 
decrease in tumor luminescence from the MS1PSMA/ID8VEGF tumors after the second 
injection of P28BBζ T cells, between days 24 and 28 (Figure 25c).  In contrast, I 
observed a significant increase in signal from the antigen negative MS1/ID8VEGF tumors 
during that same period (Figure 25c).  Upon sacrifice of the animals, I confirmed 
elimination of the MS1PSMA endothelial cells via flow cytometry (not shown).  Together, 
these data demonstrate that destruction of the vasculature does indeed result in tumor cell 
loss.   
Finally, I sought to determine whether bystander killing of adjacent ID8VEGF 
tumor cells could explain the reduction in tumor signal I observed in this model.  I 
performed an in vitro killing assay where I co-cultured MS1PSMA endothelial cells 
overnight at increasing ratios with ID8VEGF tumor cells and T cells.  MS1PSMA cells were 
eliminated by the P28BBζ CAR T cells, but the ID8VEGF cells were unaffected by the T 
cells (Figure 25d).  These data suggest that tumor regression in vivo occurred through 
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indirect loss of tumor cells, related to the disruption of the vasculature, rather than a 
direct bystander effect. 
 
The distribution of membrane-bound PSMA isoforms in normal tissue 
 One possible concern in targeting PSMA with CAR-bearing T cells is the 
potential for on target/off organ toxicity. PSMA has been detected by 
immunohistochemistry in a number of organs,50,52 (summarized in Table 5) and was 
confirmed by us using the 3E6 antibody (Table 5, Figure 26).  The interpretation of this 
data, however, is complicated by a number of factors.  I observed apical expression of 
PSMA in the ducts of the prostate, the kidney tubules, and the intestines (Figure 26), 
which others have suggested may provide a degree of immune privilege to these sites, as 
the apical surfaces of these cells are separated from circulation by tight junctions.82  This 
may explain why clinical trials performed with radiolabeled J591 antibody did not show 
localization of the antibody to either the intestine or kidney.53  Additionally, the presence 
of multiple PSMA splice variants has further complicated the direct interpretation of the 
existing immunohistochemistry data (Figure 27).  Of the known membrane-bound 
isoforms of PSMA, only isoforms 1 and 2 have confirmed physiological relevance.83  
Isoform 1 is more abundant than isoform 2, but the relative distribution of each is 
unclear.  Isoform 2 is nearly identical to full-length PSMA, but is missing exon 18.  Prior 
to this study, the J591 scFv was known to bind an extracellular epitope of PSMA, but it 
was unknown whether the antibody could distinguish between the two isoforms.  
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Therefore, I first sought to determine whether the J591-based CAR T cells could 
distinguish between PSMA isoform 1 and isoform 2.  
 Immortalized human microvascular endothelial cells (HMEC-1) were engineered 
to express either PSMA isoform 1 or 2 using lentiviral transduction.  Primary human T 
cells were then transduced to express the Pζ CAR and monitored for CAR expression 
(See Figure 8c).  Analysis of INF-γ after co-culture revealed specific activation of the 
CAR bearing T cells exclusively by the isoform 1-bearing HMEC (Figure 28).  
Importantly, this shows that the Pζ CAR T cells can distinguish between the two PSMA 
isoforms and identifies a previously unappreciated specificity for the J591 scFv.  This 
also suggested that the binding epitope for J591 lies within exon 18, as this is the only 
region missing between the two isoforms.  This observation, however, also raised 
questions concerning the distribution of the two isoforms, particularly whether 
differential expression of either isoform may occur in either normal or neoplastic tissue.  
Reliance on standard antibody-based assays to distinguish the two isoforms was unlikely 
to succeed, as extensive homology between the two isoforms exists.  I therefore utilized 
RT-PCR to distinguish between the two isoforms in a panel of normal tissues. 
 To avoid amplification of non-membrane bound variants of PSMA, I designed 
PCR primers to sit within the transmembrane region and exon 19, which are shared 
between PSMA isoform 1 and PSMA isoform 2.  Using these primers, PCR products of 
2016 bp  and 1922 bp were expected from PSMA isoform 1 and 2, respectively (Figure 
29a).  To confirm the specificity of these primers, I performed a PCR on cDNA collected 
from the transduced HMEC-1 cells, which were engineered to express either isoform 1 or 
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2, and the LNCaP prostate cancer cell line, which was previously identified to express 
both isoforms.84  Polyacrylamide gel electrophoresis revealed the expected result, and 
demonstrated that PSMA isoform 1 and 2 could be resolved using this methodology 
(Figure 29b).   
 cDNA was then collected from a panel of 20 normal tissues, and PCR for 
ribosomal RNA 18s, was performed as a loading control for each of the samples (Figure 
30).  PCR analysis of the isoforms revealed expression of both in the brain, colon, kidney 
and prostate, and to a lesser extent, the spleen, liver, lung, ovary, and placenta (Figure 
31).  Importantly, few differences in the expression of each isoforms were noted, 
indicating that the preference of the J591 scFv for isoform 1 would not likely yield a 
therapeutic advantage.  However, this study has identified a list of normal organs that 
should be monitored carefully during the administration of anti-PSMA CAR-bearing T 
cells, and underscores the importance of developing safety features for CAR therapy 
(discussed in detail within Chapter 4).  In addition, this study confirms the presence of 
PSMA isoform 2 in a number of tissues, and highlights the need for further study of this 
isoform in normal physiology.   
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Conclusions 
  Although numerous studies have demonstrated the anti-tumor effect of CAR T 
cells, only a small selection of these have focused on the ability of engineered T cells to 
disrupt the vasculature.  Here, I have shown that T cells bearing a CAR against PSMA 
can mediate vascular disruption, which leads to tumor regression.  In vitro, the P28BBζ T 
cells were capable of recognizing and eliminating endothelial targets (Figure 11), as well 
as microvessels formed from these cells (Figure 14).  In addition, the P28BBζ CAR T 
cells were able to eliminate hemangiomas as well as hemangiosarcomas in vivo (Figure 
16–18).  Lastly, in two solid ovarian tumor models, I found that administration of the 
P28BBζ T cells was able to eliminate PSMA+ tumor vasculature, and result in the loss of 
tumor cells as well as elicit tumor regression (Figure 21–25).   Taken together, these data 
support the observation that CAR T cells can effectively disrupt the tumor vasculature, 
and that elimination of the vasculature by antigen specific T cells can result in tumor 
regression.  Complete eradication of solid tumor was not observed in these models, 
however, and future studies should aim to address this shortcoming through 
combinatorial approaches.  Conventional VDAs have demonstrated synergy with 
radiation, chemotherapy, and anti-angiogenic therapies, suggesting a role for such 
combinations in CAR mediated vascular disruption.85  Even so, it should be noted that 
this is the first study to demonstrate that CAR bearing T cells are able to eliminate 
PSMA+ vasculature within the tumor, and that elimination of these cells can have 
profound effects on tumor progression.  As such, this work supports the further 
development of anti-PSMA CAR T cells for use in vascular disruption therapy.  
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
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Recent clinical trials have demonstrated the power of CAR T cell-based 
immunotherapy for individuals with advanced cancer.  Remarkable responses have been 
reported, for example, in patients receiving CD19-specific CAR T cell therapy for the 
treatment of acute lymphocytic leukemia.24,36,86 In addition, active remission has been 
reported in patients with neuroblastoma after treatment with CAR T cells directed against 
the ganglioside, GD2.87 A critical component to the clinical success of adoptive CAR T 
cell treatment is the choice of target antigen.  Ideally the target is immunogenic, related to 
oncogenesis, and is stably, selectively, and abundantly expressed in tumor tissue.  
Recently, we and others have shifted focus towards targeting the tumor vasculature, as 
opposed to the tumor itself, since these cells represent a more ‘universal’ and genetically 
stable target.23,88  Not only would this strategy cut off oxygen and nutrient exchange to 
the tumor, as well as important growth factors, but it would also breakdown a physical 
barrier against immune cell inflitration.89 One tumor endothelial-specific target is TEM1.  
The potency of generating a T cell response against this antigen is evident through studies 
using DNA vaccines.23  The development of CAR T cells against this antigen, however, 
has been difficult.  I was able to generate a T cell response against plate-bound 
recombinant TEM1 protein using the scFv78 CAR, but was unable to demonstrate 
reactivity against TEM1 expressed on the surface of endothelial cells.  This suggests that 
the epitope targeted by scFv78 may be “masked” by the milieu of surface proteins on the 
target cells or that it may be too distal from the CAR receptor to properly engage, as 
soluble scFv78 was able to label TEM1 on the surface of these cells.  These data 
underscore a largely underappreciated aspect of CAR development and stress the 
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importance of epitope accessibility when choosing a scFv for use in CAR.  Finally, I have 
also shown that T cells bearing a CAR against PSMA, an antigen upregulated on the 
tumor endothelium in many types of cancer, can destroy the tumor vasculature and elicit 
tumor regression.  Together, the wide expression of PSMA across many solid tumor 
types, and the ability of the P28BBζ T cells to elicit tumor regression through vascular 
disruption, justifies the pursuit of this therapeutic approach.  
One major advantage of using CAR T cells to disrupt the tumor vasculature, as 
opposed to conventional VDAs, is their ability to self-replicate and to persist long-term in 
patients.24 In addition, CAR T cells can trigger epitope spreading and help to reprogram 
the tumor microenvironment.25 Given the persistence and power of CAR T cells, a 
second critical component to the clinical success of CAR T cell therapy is safety.  This 
cannot be overstated, as unexpected CAR cross-reactivity with healthy tissues has, 
unfortunately, resulted in patient deaths.87 Prior to this study, tumor blood vessels 
destruction had been successfully demonstrated using CAR T cells engineered to 
recognize VEGFR-1 and VEGFR-238 or VEGFR-2 alone.37 Although encouraging, 
VEGF receptors are also expressed by normal endothelial cells throughout the body and 
thus represent a significant risk for “on-target/off-tumor” toxicity.  In contrast, PSMA has 
not been found on normal blood vessels.  Nevertheless, it has been detected by IHC in the 
prostate, kidney, liver, intestine, and colon, as well as on the astrocytes of the brain.52,90,91 
Discrepancies exist between these studies, however, and interpretation of the data is 
complicated by the existence of splice variants,62,63 the localization of the protein on the 
cell surface (apical versus basal), the process of tissue collection, the method of fixation, 
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and the antibodies used to detect PSMA.  Recognition of PSMA by the CAR T cells 
described here is mediated through the well-characterized scFv, J591.  Encouragingly, 
imaging studies performed with radiolabeled J591 did not show accumulation of the mAb 
in either the kidneys or the small intestine.53 Furthermore, a phase 1 clinical trial with the 
J591 mAb demonstrated positive localization of the antibody to tumors with PSMA+ 
vasculature.92 Overall, this evidence suggests that J591-based CAR T cells will have a 
favorable safety profile in patients.     
Additional approaches exist, however, that could increase the safety of CAR 
bearing T cells against both the tumor and/or the tumor vasculature.  In mice, CAR T 
cells generated through RNA transfection were seen to approach the efficacy of 
lentivirally transduced T cells when given in multiple administrations after 
lymphodepleting chemotherapy.93  These T cells have the advantage of losing CAR 
expression over time, through cellular division and mRNA degradation, and offer a 
potential solution to the “on-target/off-tumor” reactivity of persistent T cells after tumor 
elimination.  Another approach to eliminate these cells would be to include a “suicide 
switch”, such that the CAR-bearing T cells could be selectively eliminated through the 
administration of a drug or pro-drug.  Herpes simplex thymidine kinase (HSV-tk) was the 
first robustly tested inducible suicide gene, and administration of the drug ganciclovir 
was shown to result in the death of cells harboring HSV-tk.  However, further study 
demonstrated that HSV-tk can be immunogenic,94 and that silencing of the gene can 
result in ganciclovir-resistance,95 ultimately leading to the search for additional genes.  
More recently, inducible activation of caspase 9 (iC9) has gained favor.  In patients, it 
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was demonstrated that T cells carrying the iC9 gene could be selectively eliminated from 
those experiencing graft versus host disease (GVHD) by treatment with the dimerizing 
drug, AP1903.96  In these patients, symptoms of GVHD resolved with the destruction of 
the transduced T cells.  In a mouse model of non-Hodgkins lymphoma, 3rd generation 
CAR T cells, like the P28BBζ T cells used here, were also found to be susceptible to 
inducible apoptosis by the iC9 suicide gene,97  Finally, CAR T cells could be engineered 
to contain split-signaling CARs where signal 1 (CD3ζ) would be linked to a scFv 
recognizing one target while signal 2 (such as CD28 and/or 4-1BB) would be linked to a 
second scFv recognizing another target.  This has been demonstrated by Lanitis et. al.,59 
and could be applicable for vascular targeting, for example, using CAR T cells 
engineered to recognize PSMA (signal 1) and a second tumor endothelial target, thus 
providing increased therapeutic safety. Additional tumor endothelial targets have been 
identified in ovarian cancer5,98 and other tumors,40 enabling these combinatorial designs. 
The heterogeneous expression of PSMA on the tumor vasculature may represent a 
significant obstacle for PSMA-directed anti-vascular therapy.  Here I found that over 
85% of women with ovarian cancer expressed PSMA on their tumor vasculature, but also 
that only 40–60% of the CD31+ endothelial cells isolated from their gynecological tumors 
expressed PSMA.  The biology of this heterogeneity has not yet been investigated. It is 
possible that upregulation of PSMA reflects a state of metabolic activation of tumor 
endothelial cells, requiring increased folate uptake.  In fact, PSMA exhibits hydrolase 
activity, which hydrolyzes the gamma-glutamyl tail of folate polyglutamates, resulting in 
folates that can be readily taken up by cells. At physiological folate concentrations, 
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overexpression of PSMA was found to confer growth advantage to tumor cells and 
enhance their invasive activity.65 Importantly, angiogenesis is severely impaired in 
PSMA-null mice and the enzymatic activity of PSMA is required for endothelial cell 
invasion in vitro through regulation of integrin signaling.67 Therefore, PSMA-expressing 
endothelial cells may be critical for neovascular formation, and their persistent immune-
mediated elimination could not only disrupt the existing vasculature but also prevent new 
blood vessel formation.  This hypothesis has not yet been fully tested, and it remains to 
be seen whether anti-PSMA CAR T cells could influence the re-generation of tumor 
blood vessels through this mechanism.  It is worth noting, however, that in my adoptive 
CAR T cell transfer studies the P28BBζ T cells were able to persistently suppress almost 
the entire PSMA-expressing fraction of tumor endothelial cells.  
Unfortunately, elimination of the PSMA+ vessels from the MS1PSMA/ID8VEGF 
tumor model did not result in complete tumor regression.  This could be due to the fact 
that only a fraction of the tumor endothelial cells expressed PSMA within this model, as 
was the case for the human tumor specimens I analyzed.  One method to overcome this 
obstacle would be to combine the anti-PSMA CAR T cells with additional treatment 
modalities.  Conventional VDAs have been combined with both radiation and 
chemotherapy for improved tumor control,85 suggesting that a similar approach could 
also augment the efficacy T cell mediated vascular disruption.  In addition, VDAs have 
also been successfully administered with anti-angiogenic agents as a means to target the 
existing tumor blood vessels, as well as impair the growth of new vessels.99 In fact, anti-
angiogenic therapy has already been shown to synergize with CAR T cell therapy (1st 
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generation) directed against the VEGF receptors.38 Another approach to increase the 
efficacy of the anti-PSMA CAR T cells would be to combine them with CAR T cells or 
TCR-engineered T cells that recognize a second tumor endothelial antigen or the tumor 
itself.  The group of Steven Rosenberg illustrated this approach by showing that B16 
tumors could be successfully eradicated in mice when anti-VEGFR-2 CAR T cells were 
combined with tumor-targeting T cells, but not when the mice were treated with the anti-
vascular CAR T cells alone.100 Building on this observation, I also posit that patients 
whose tumor expresses PSMA on both the endothelium and tumor, as was observed here 
for one subject with ovarian cancer and has been noted in a number of cancers,52 may 
respond more successfully to treatment with anti-PSMA T cells.  The answer to this 
question continues to be pursued within our lab.   
In conclusion, I have demonstrated that 3rd generation CAR T cells can target and 
eliminate PSMA-expressing endothelial cells of the tumor vasculature both in vitro and in 
vivo, and that elimination of these cells can result in tumor regression.  I propose that 
split-signaling may enhance their safety profile, and that, in combination with other 
treatments such as chemotherapy, radiation, and/or tumor cell targeting T cells, they will 
provide important clinical benefit to patients. 
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CAR construction 
The J591 35 and MOv19 69 scFvs were gifts from M. Sadelain and D. Powell, 
respectively.  The pELNS lentiviral vector and the genes encoding the CAR signaling 
domains ζ, 28ζ, BBζ, and 28BBζ were gifts from C. June.34  pELNS is a third generation 
self-inactivating lentiviral expression cassette based on pRRL-SIN-CMV-eGFP-WPRE;58 
with transgene expression driven by the EF-1α promoter.  The constructs were 
engineered to express an upstream eGFP reporter separated from the CAR by a T2A 
sequence.  The J591 and MOv19 scFvs were amplified via PCR and subcloned into an 
intermediary vector (pCLPS) using 5’ BamHI and 3’ NheI restriction enzyme cut sites.  
5’ primer, J591F = ATCGggatccGTGCAGCTGCAGCAGTCAGG and 3’ primer, J591R 
= GCTAgctagcCCGTTTCAGGTCCAGCATGG. BamHI and NheI cut sites are 
underlined, respectively.  The resulting constructs contained the full-length CAR 
construct, including signaling domain(s).  The full-length sequence for each CAR was 
then isolated from the pCLPS vectors using 5’ AvrII and 3’ SalI restriction enzyme cut 
sites.  Finally, the CAR constructs were ligated into the pELNS vector backbone, which 
was gel-purified after digestion with XbaI (compatible with AvrII) and SalI restriction 
enzymes.  The anti-TEM157 and anti-mesothelin (P4)59 CARs were constructed in a 
similar manner using primers directed against their respective scFvs. 
 
Lentiviral production 
Lentivirus was generated as previously described.59  Briefly, 2.0×106 293T cells 
were plated in T-150 tissue culture flask 18 h before transfection with transgene (15 µg, 
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pELNS) and packaging plasmids (7 µg pVSV-G, 18 µg pRSV-REV, and 18 µg 
pMDLg/p.RRE).  Supernatants were collected at 24 and 48 h and were then combined 
and concentrated via ultracentifugation at 28,000 RPM for 3 h.  Virus was re-suspended 
in 2 mL RPMI (10% FBS, 100 IU mL–1 penicillin, and 100 µg mL–1 streptomycin 
sulfate), flash frozen, and stored at –80° until needed.   
 
Human T cell Transduction 
T cells were isolated from healthy donors by the Human Immunology Core at the 
University of Pennsylvania under a protocol approved by the University Institutional 
Review Board.  With minor modifications, T cells were transduced as previously 
described.59  Briefly, T cells were cultured in RPMI supplemented with 10% FBS, 100 IU 
mL–1 penicillin, and 100 µg mL–1 streptomycin sulfate.  20 h prior to transduction, 
5.0×105 T cells were activated using anti-CD3/anti-CD28 coated beads (Invitrogen, 
Carlsbad, CA) at a 2:1 bead to T cell ratio in RPMI supplemented with 50 IU mL–1 
recombinant human IL-2 (Peprotech, Rocky Hill, NJ).  Activated T cells were 
spinoculated at 1000 g for 90 min with lentivirus (MOI of 10) and polybrene (8 µg mL–1; 
Sigma-Aldrich, St. Louis, MO) in a total volume of 1 mL.  24 h after spinoculation, half 
the media was removed (0.5 mL) and cells were given 1.5 mL of fresh RPMI with 50 IU 
mL–1 recombinant human IL-2.  The media was replenished every other day with fresh 
RPMI and IL-2 (50 IU mL–1) so that T cell density did not exceed ~1.0×106 mL–1.  The T 
cells were used between 14–28 d after transduction. 
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Cell lines 
Low-passage (P16) 293T cells purchased from the American Type Culture 
Collection (ATCC, Manassas, VA) were used for the production of lentivirus particles.  
The MS1 (mouse pancreatic islet) endothelial cell line was also purchased from the 
ATCC.  Immortalized H5V (mouse heart endothelial cells) were previously acquired.75  
293T, MS1, and H5V cell lines were grown in RPMI supplemented with 10% FBS, 100 
IU mL–1 penicillin, and 100 µg mL–1 streptomycin sulfate.  HMEC-1 cells, an SV40 
transformed human microvascular endothelial cell line,70 were obtained from the Centers 
for Disease Control and Prevention (Atlanta, GA) and grown in MCDB 131 media 
(Invitrogen, Carlsbad, CA) containing mouse EGF (BD, Franklin Lakes, NJ), 
hydrocortisone (Sigma-Aldrich, St. Louis, MO), 10% FBS, 100 IU mL–1 penicillin, and 
100 µg mL–1 streptomycin sulfate and 1x GlutaMax (Invitrogen, Carlsbad, CA).   
 
Flow Cytometry 
CAR T cells were identified primarily through detection of their eGFP reporter.  
For surface detection, T cells were stained with an APC-conjugated goat anti-mouse 
F(ab2) fragment (Jackson, West Grove, PA; #115-136-072).  Bcl-xL expression was 
detected using a mouse anti-human Bcl-xL Ab (SouthernBiotech, Birmingham, AL; 
clone 7B2.5) after fixation and permeabilization with an intracellular staining kit 
(eBioscience, San Diego, CA).  PSMA was detected using a humanized J591 mAb (gift 
from N. Bander) and an APC-conjugated anti-human secondary Ab (Jackson, West 
Grove, PA; #109-136-098).  Positive staining was assessed by comparison with a human 
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IgG isotype control Ab (Enzo, Farmingdale, NY; #ALX-804-133-C100).  In addition to 
the J591 mAb, human tumor digests were stained with APC-Cy7-conjugated anti-human 
CD45 (BD, Franklin Lakes, NJ; clone 2D1), Pacific-Blue-conjugated anti-human CD31 
(BioLegend, San Diego, CA; clone WM59), and PE-conjugated anti-folate receptor 
(R&D, Minneapolis, MN; clone 548908) Abs prior to analysis.  Harvested mouse tumors 
were also stained with the J591 mAb, as well as APC-Cy7-conjugated anti-human CD45 
(BD, Franklin Lakes, NJ; clone 2D1) and Pacific-Blue-conjugated anti-mouse CD31 
(BioLegend, San Diego, CA; clone 390) Abs.  All samples were stained with the fixable 
viability dye eFlour 506 prior to analysis (eBioscience, San Diego, CA).     
 
T cell proliferation studies 
Prior to co-culture with target cell lines, T cells were labeled with CellVue® 
Claret as described in the kit’s technical bulletin (Sigma-Aldrich, St. Louis, MO).  
Labeling was confirmed by flow cytometry prior to co-culture.  1.0×105 CAR T cells 
were then cultured with 5.0×104 HMEC-1 or HMEC-1PSMA (E:T = 2:1) for 5 days in 48-
well flat-bottom plates.  Flow cytometry was used to analyze the intensity of CellVue® 
staining after co-culture.  CAR+ T cells were identified by eGFP expression.  To quantify 
the membrane staining between the T cells cultured with the HMEC-1 versus HMEC-
1PSMA, the geometric mean fluorescence intensity (MFI) of Cellvue® Claret staining was 
measured for the CAR-positive T cells.  To normalize across multiple donors, the MFI of 
CellVue® staining on CAR+ T cells after co-culture with HMEC-1PSMA was divided by 
the MFI of the CAR+ T cells after co-culture with the HMEC-1.      
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Cytokine Release Assays 
IFN-γ ELISAs were performed as directed in the Human IFN-γ ELISA MAX 
technical manual (BioLegend, San Diego, CA).  For co-culture of CAR T cells with 
immobilized protein, recombinant TEM1 or BSA was coated onto an adsorbent nunc 
plates at 2.5 µg mL-1 overnight using carbonate/bicarbonate buffer.   1.25×105 T cells 
were added to each well and cultured overnight (18 h) before supernatants were collected 
and analyzed by IFN-γ ELISA.  For cell line assays, 7.5×104 CAR T cells were cultured 
overnight with 2.5×104 endothelial targets (E:T = 3:1), unless otherwise noted in the 
figure legends.  Triplicate cultures were performed in 96-well flat-bottom plates.   
Supernatants were collected from each well after 18 h.  For assays utilizing primary 
human tumor samples, 9.0×104 CAR T cells were cultured overnight with 3.0×104 
enriched endothelial targets (E:T = 3:1).  Cultures were performed in 96-well flat-bottom 
plates and supernatants were collected after 18 h.    
 
Biotin Binding Immune Receptor Assays 
Lentivirus was for the BBIR was generously given donated by the laboratory of 
Daniel Powell.  T cells harboring the BBIR were plated with labeled targets at ratios 
described in the figure legends.  Prior to co-culture, cells were detached from tissue 
culture plates using 2mM EDTA and labeled using biotinylated anti-TEM1 antibodies at 
a concentration of 2.5 µg mL-1.  Half the labeled cells were used for flow cytometry to 
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confirm binding, whereas the other half of the cells was utilized in co-culture.  Co-
cultures were performed overnight (18 h), at which point supernatants were collected for 
analysis for IFN-γ by ELISA. 
   
Cytotoxicity assays 
51Cr release assays were performed as previously described 59. CAR T cells were 
cultured for 18 h with endothelial targets at E:T ratios of 10:1, 3:1, and 1:1.  Specific lysis 
was calculated as (experimental – spontaneous lysis / maximal – spontaneous lysis) × 
100.  Luciferase based assays were performed similarly; CAR T cells were co-cultured 
for 18 h with endothelial targets engineered to express firefly luciferase at the ratios 
indicated in the figure legend(s).  Co-cultures were performed in triplicate using opaque 
96-well flat-bottom plates in phenol-free RPMI.  Firefly luminescence measurements 
were taken according to Luc-Screen® technical manual (Life Technologies, Grand 
Island, NY).  The percentage of specific lysis was calculated as 100 – (luciferase signal 
treated / luciferase signal untreated × 100). 
 
Time-lapse microscopy 
24-well flat-bottom plates were coated with a thin layer (300 µL per well) of 
Matrigel (BD, Franklin Lakes, NJ) and allowed to solidify at 37° C for 30 min.  Next, 
either 1.0×105 HMEC-1 or 1.0×105 HMEC-1PSMA endothelial cells were seeded into the 
wells.  Microvessels were given 8 h to form prior to addition of the CAR T cells.  After 8 
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h, 3.0×105 CAR T cells were added to each well and images were taken at 0, 24, and 48 h 
after initiation of the co-culture (E:T = 3:1).  Cells were kept in an environmentally 
controlled chamber at 37° C with 5% CO2 throughout the experiment.  X-Y coordinates 
were saved for each well so that the identical field of view could be captured at each time 
point.  Pictures were taken using a fluorescence microscope (ECLIPSE Ti; Nikon 
Corporation, Tokyo, Japan) equipped with a charge-coupled device camera (Photometrics 
CoolSnap HQ2; Roper Industries, Inc, Sarasota, FL, USA) and NIS-Elements AR 
software (v 3.2; Nikon Corporation).  Original magnification shown, 40× or 100×, as 
described in the figure legends.   
 
Immunohistochemistry 
For human TMA and normal organ slide staining, paraffin-embedded tissues were 
baked at 60 ˚C for 1 h, deparrafinized in xylenes, rehydrated in sequential gradations of 
alcohol, and washed in water.  Depending on the Ab, antigen retrieval was performed 
using either citrate or EDTA buffer.  Endogenous peroxidase was inactivated with Dual 
Endogenous Enzyme block (Dako, Carpnteria, CA). Following Ab staining, TMAs were 
visualized with diaminobenzidine tetrahydrochloride (Dako, Carpnteria, CA) or an 
alkaline phosphatase red substrate kit (dual stains).  Sections were then counterstained 
with hematoxylin. Sections were stained with an anti-human PSMA Ab (Dako, 
Carpnteria, CA; clone 3E6) alone, or in combination with anti-human CD34 Ab (Thermo 
Scientific, Waltham, MA; rabbit polyclonal).  The TMAs and slides were then scanned 
and analyzed using ImageScope software.  For TMAs that included multiple cores from 
57 
the same subject, individuals were considered PSMA+ if staining could be confirmed on 
any of the cores from that subject.  Damaged or absent cores were excluded from 
analysis.      
    
Enrichment of human CD31+ endothelial cells 
Human tumor specimens were gathered with approval from the UPENN 
institutional review board in compliance with the US Health Insurance Portability and 
Accountability Act (HIPAA).  Briefly, tumors were mechanically or enzymatically 
digested to yield a single cell suspensions that were subsequently frozen and stored at –
150° C until needed.  Samples were rapidly thawed in a 37° C water bath.  Viable cells 
were counted using Trypan Blue.  Tumor digests were first depleted for CD45 using 
Miltenyi anti-human CD45 beads, as per manufacturers instructions (Miltenyi, San 
Diego, CA).  The CD45– fraction was then enriched for human CD31 endothelial cells 
using Miltenyi anti-human CD31 beads (Miltenyi, San Diego, CA).  Both the CD45–
CD31– and CD45–CD31+ population were retrieved and analyzed by flow cytometry 
and/or used in functional assays. 
 
  RT-PCR of PSMA isoforms in normal tissues 
A panel of normal tissue human RNA was obtained through Ambion/Life 
Technologies (FirstChoice® Human Total RNA Survey Panel, Grand Island, NY).  Each 
RNA sample was pooled from at least three distinct donors.  cDNA was synthesized 
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using the SuperScript® First Strand Synthesis kit (Life Technologies, Grand Island, NY).  
PCR for the internal control reference gene, ribosomal RNA 18s, was performed to 
confirm equivalent starting concentrations of cDNA.  (18s Forward: 5’-
CAGCCACCCGAGATTGAGCA-3’, 18s Reverse: 5’-
TAGTAGCGACGGGCGGTGTG-3’)(25 cycles at: denaturation: 94°, annealing: 52°, 
elongation 72°).  PCR for PSMA isoforms 1 and 2 were performed using primers specific 
to the transmembrane and exon 19 regions shared between the two isoforms. (PSMA 
TMF: 5’-CTGGTGCTGGCGGGTGGCTTC-3’, PSMA 19R: 5’- 
GTGGCTGCTTGGAGCATAGATG-3’)(38 cycles at: denaturation: 92°, 
annealing/elongation 68°).  Samples were run on a 5% polyacrylamide gel using gel 
electrophoresis and visualized using a gel imaging station.    
 
Mice 
All protocols were reviewed and approved by the Institutional Animal Care and 
Use Committee at the University of Pennsylvania.  All experiments were done using 
female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice (aged 8-10 weeks) purchased from 
and housed at the Stem Cell Xenograft Core (SCXC), a germ-free facility at University of 
Pennsylvania. 
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In vivo assays with HMEC-1 cells 
Matrigel plugs containing HMEC-1 (left flank) and HMEC-1PSMA (right flank) 
endothelial cells were injected s.c. on the flanks of mice.  CAR-positive T cells were 
administered via tail vein injection immediately following implantation of the plugs.  The 
number of cells inoculated/injected is notated in the figure legend(s).  Mice were 
sacrificed after 11 days and the Matrigel plugs retrieved and digested with 3U mL–1 
dispase (Sigma-Aldrich, St. Louis, MO) and 25 µg mL–1 DNase to yield a single cell 
suspension.  The cells collected from the plugs, as well as splenocytes collected from the 
spleens of the sacrificed animals, were then stained and analyzed by flow cytometry. 
 
In vivo assays with MS1 cells 
Mice were injected s.c. on each flank with MS1 (left flank) and MS1PSMA (right 
flank) endothelial cells and CAR-bearing T cells were administered as noted in the figure 
legend(s).  Hemangioma development and response to treatment was monitored twice a 
week by measuring luciferase luminescence.   Mice were injected intraperitoneally with 
100 µL of D-Luciferin stock solution (30 mg mL–1, GoldBio, St. Louis, MO), 
anesthetized using isofluorane, and imaged 20 min after luciferin injection.   To avoid 
bias, the PSMA+ tumor (right flank) was measured first.  Mice were then flipped, and the 
antigen negative tumor (left flank) was analyzed, typically 1-2 minutes after the right 
flank.  Data were gathered using a Xenogen IVIS imaging system, and analyzed using 
Living Image software (PerkinElmer, Waltham, MA).  When palpable, tumors were 
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measured with Vernier calipers and volumes were calculated using the equation V = ½ (L 
✕ W2).   
 
In vivo assays with H5V cells 
Mice were injected i.v. with H5VPSMA endothelial cells and CAR T cells were 
administered as noted in the figure legend(s).  Tumor development and response to 
treatment was monitored twice a week by measuring luciferase luminescence.  Mice were 
injected with luciferin as described above.  Luciferin was injected as described above and 
20 min after injection the ventral surface of the animals was imaged.  Mice were weighed 
twice per week and sacrificed if/when they lost more than 10% of their initial body mass.   
 
In vivo assays with MS1/ID8 cells 
Mice were injected s.c. on each flank with MS1/ID8 (left flank) and 
MS1PSMA/ID8 (right flank) cells and CAR T cells were administered as noted in the 
figure legend(s).  Luciferase luminescence and tumor volume were measured as 
described for the MS1 tumors.  After termination of the MS1/ID8VEGF experiment, the 
remaining tumors were excised and split for analysis.  Half the tumor was embedded and 
frozen in Tissue-Tek® O.C.T. medium (VWR, Philadelphia, PA), while the other half 
was digested overnight in serum free RPMI containing collagenase (175 CDU mL–1) and 
DNAse (20 Kunitz units mL–1).  After digestion, tumors were filtered through a 70 µm 
mesh filter and treated with ACK buffer to lyse red blood cells.  Digests were then 
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analyzed by flow cytometry.  Tumors not large enough to be split were embedded in 
O.C.T. and frozen.  For the ID8VEGF, MS1/ID8VEGF, MS1PSMA/ID8VEGF control mice 
eGFP radiance was also measured.   The ID8VEGF tumor cells brightly express an eGFP 
reporter (data not shown).  Spectral unmixing for eGFP was performed using the Living 
Image software, and the results were plotted against luciferase luminescence values taken 
concurrently.  Finally, ID8VEGF cells were also transduced to express firefly luciferase.  
For experiments utilizing these tumor cells, non-luciferase bearing MS1 cells were co-
injected with the ID8VEGF so that the signal from the tumor could be visualized 
independently without reflecting the contribution of the MS1 derived vasculature. 
 
Statistical Analysis 
Values are expressed as the mean ± either SD or SEM, as indicated in the figure 
legends. Statistical differences were determined to be significant at P < 0.05. Specific 
tests used are described in the figure legends. All analyses were performed using 
Graphpad Prism Software. 
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Table 1: Key differences between anti-angiogenic therapy and vascular disruption 
therapy.  (Used with permission)17 
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Table 2: PSMA expression on the tumor vasculature, a summary of selected studies. 
  
Tumor Type Number (%) Number (%) Number (%) Number (%) Number (%) Number (%) Number (%) Number (%)
Wernicke et al1 Haffner et al4Samplaski et al3Abdel-Hadi et al2 Haffner et al5 Denmeade et al6 Silver et al7 Chang et al8
Study
68/92 (74%)
Oral Cancer
Non-small cell lung carcinoma
Melanoma
Hepatocellular Cancer
Gastric Cancer
Colorectal Carcinoma
Breast Cancer
Bladder Cancer
Renal Cancer
Pancreatic ductal carcinoma
Ovarian Cancer
75/100 (75%)
8/167 (5%)
72/96 (75%)
110/130 (85%)
79/119 (66%)
40/94 (43%)
34/44 (75%)
39/41 (95%)
25/44 (57%)
25/34 (75%)
44/46 (95%)
68/92 (54%)
3/29 (16%)
8/17 (47%)
5/6 (83%)
5/5 (100%)
5/5 (100%)
5/5 (100%)
4/4 (100%)
11/11 (100%)
1 Wernicke, AG, Varma, S, Greenwood, EA, Christos, PJ, Chao, KS, Liu, H, et al. (2014). Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 122: 482-
489.
2 Abdel-Hadi, M, Ismail, Y, and Younis, L (2014). Prostate-specific membrane antigen (PSMA) immunoexpression in the neovasculature of colorectal carcinoma in Egyptian patients. Pathology, research and practice.
3 Samplaski, MK, Heston, W, Elson, P, Magi-Galluzzi, C, and Hansel, DE (2011). Folate hydrolase (prostate-specific membrane [corrected] antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Modern pathology : an official journal of the 
United States and Canadian Academy of Pathology, Inc 24: 1521-1529.
4 Haffner, MC, Kronberger, IE, Ross, JS, Sheehan, CE, Zitt, M, Muhlmann, G, et al. (2009). Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Human pathology 40: 1754-1761.
5 Haffner, MC, Laimer, J, Chaux, A, Schafer, G, Obrist, P, Brunner, A, et al. (2012). High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Modern 
pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 25: 1079-1085.
6 Denmeade, SR, Mhaka, AM, Rosen, DM, Brennen, WN, Dalrymple, S, Dach, I, et al. (2012). Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Science translational medicine 4: 140ra186.
7 Silver, DA, Pellicer, I, Fair, WR, Heston, WD, and Cordon-Cardo, C (1997). Prostate-specific membrane antigen expression in normal and malignant human tissues. Clinical cancer research : an official journal of the American Association for Cancer Research 3: 81-85.
8 Chang, SS, Reuter, VE, Heston, WD, Bander, NH, Grauer, LS, and Gaudin, PB (1999). Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer research 59: 3192-3198.
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Table 3: Affinity of the anti-TEM1 scFvs.  The comparative affinity of the anti-TEM1 
scFvs, as determined by ELISA.57   
 
  
scFv% Aﬃnity%
scFv78' 2'nM'
scFv131' 1'μM'
scFv132' 280'nM'
scFv133' 480'nM'
scFv137' 4.8'μM'
78 
 
 
Table 4: PSMA expression is heterogeneously expressed on blood vessels within the 
tumor.  
  
Tumor Type 
Less than 50% tumor vessels 
 expressing PSMA 
Percentage 
Bladder Cancer NA 10-100%1 
Breast Cancer 26/48 54%2 
Colorectal Carcinoma 52/75, 52/130 69%3, 40%4 
Gastric Cancer 56/79 71%4 
Oral Cancer 48/72 67%5 
1 Samplaski, MK, Heston, W, Elson, P, Magi-Galluzzi, C, and Hansel, DE (2011). Folate hydrolase (prostate-specific membrane 
[corrected] antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Modern pathology : an 
official journal of the United States and Canadian Academy of Pathology, Inc 24: 1521-1529. 
2 Wernicke, AG, Varma, S, Greenwood, EA, Christos, PJ, Chao, KS, Liu, H, et al. (2014). Prostate-specific membrane antigen 
expression in tumor-associated vasculature of breast cancers. APMIS : acta pathologica, microbiologica, et immunologica 
Scandinavica 122: 482-489. 
3 Abdel-Hadi, M, Ismail, Y, and Younis, L (2014). Prostate-specific membrane antigen (PSMA) immunoexpression in the 
neovasculature of colorectal carcinoma in Egyptian patients. Pathology, research and practice. 
4 Haffner, MC, Kronberger, IE, Ross, JS, Sheehan, CE, Zitt, M, Muhlmann, G, et al. (2009). Prostate-specific membrane antigen 
expression in the neovasculature of gastric and colorectal cancers. Human pathology 40: 1754-1761. 
5 Haffner, MC, Laimer, J, Chaux, A, Schafer, G, Obrist, P, Brunner, A, et al. (2012). High expression of prostate-specific 
membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the 
oral cavity. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 25: 
1079-1085. 
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Table 5: PSMA expression in normal tissues as indicated by immunohistochemistry.   
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Figure 1: A Comparison of the normal vasculature with the tumor vasculature.  (a) 
An image of normal vessels within the lung exhibiting regular spacing and organized 
structure.  Obtained using a scanning electron microscope (SEM).  (b) A SEM image of a 
sigmoidal adenocarcinoma in which the irregular and torturous phenotype of the tumor 
vasculature can be observed, as well as abnormal bulges (arrows) and blind ends 
(circles).  Scale bar = 100 µm.  (c,d) Oxygenation in normal and tumor vascular networks 
as visualized by computer software.  (Used with permission)17  
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Figure 2: Comparison of anti-angiogenic therapy with vascular disruption therapy. 
Destruction of the tumor vasculature using vascular disruption agents results in necrosis 
of the central tumor mass.  Tumor cells survive at the periphery of the neoplasm, as they 
can obtain oxygen and nutrient exchange through adjacent tissues.  In contrast, anti-
angiogenic therapy aims to halt the recruitment of new tumor blood vessels, thereby 
slowing tumor growth. (Used with permission)7 
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Figure 3: A schematic representation of a chimeric antigen receptor.  CARs are 
generated by fusing an antigen-binding domain (most often a scFv) to the intracellular 
signaling domains of TCR, frequently CD3ζ.  Co-stimulatory domains may also be 
utilized, and may include the signaling domains from CD28 or CD137/4-1BB.  (Used 
with permission)101 
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Figure 4: Design of a CAR against TEM1. (a) Schematic representation of the anti-
TEM1 CARs.  scFv78, 131, 132, 133, or 137 was cloned downstream of the EF-1 
promoter and an eGFP reporter, which is separated from the scFv by a 2A cleavage 
sequence.  All CARs contain the CD3ζ signaling domain.  (b) Representative CAR 
expression on primary human T cells for all five anti-TEM1 CARs.  Six days after 
transduction, eGFP signal was measured using a flow cytometer.  (c) CAR surface 
detection correlates with eGFP.  Primary human T cells were transduced with lentivirus 
containing the scFv78ζ CAR.  T cells were stained for CAR expression 6 days after 
transduction using a biotinylated goat anti-mouse F(ab’)2 fragment followed by 
streptavidin-APC secondary.  
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Figure 5: 78ζ CAR-bearing T cells recognize plate-bound immobilized TEM1 
protein, but not TEM1 on the surface of target cell lines. (a) IFN-γ production by T 
cells harboring anti-TEM1 CARs in response to recombinant TEM1 protein.  CAR T 
cells were co-cultured overnight in wells previously coated with BSA, recombinant 
TEM1 protein, or the anti-CD3 antibody OKT3.  IFN-γ ELISAs were performed on the 
collected supernatants.  Representative experiment from a single donor shown.  Data are 
means ±SD from duplicate wells.  (b) Detection of TEM1 on the surface of the MS1 or 
MS1TEM1-transduced mouse endothelial cell lines.  TEM1 was detected using soluble 
scFv78 followed by APC-conjugated anti-V5 antibody.  (c) IFN-γ production by 78ζ 
CAR T cells following co-culture with target cell lines.  Overnight co-cultures were 
performed with T cells and target cells at an E:T ratio of 5:1.  The human ovarian cancer 
cell line, A1847, was used as a positive control for the P4ζ control CAR, as this line 
expresses mesothelin but not TEM1.  IFN-γ ELISAs were performed on the collected 
supernatants.  Representative experiment from a single donor shown.  Data are means 
±SD from duplicate wells.     
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Figure 6: Hinge extension does not improve the ability of the scFv78 CAR to 
recognize TEM1 on the cell surface. (a) Comparison of the amino acid sequence for the 
CD8α and IgG4 hinge domains.  (b) Schematic representation of the IgG4 hinge domain. 
(Used with permission)102 (c) IFN-γ production of CAR T cells containing either the 
CD8α or IgG4 hinge domain, after co-culture with MS1 endothelial targets.  Overnight 
co-cultures were performed with T cells and target cells at an E:T ratio of 5:1.  IFN-γ 
ELISAs were performed on the collected supernatants.  Data are means ±SD from 
duplicate wells.  (d)  Specific lysis of endothelial cell lines after overnight co-culture with 
T cells containing either the CD8α or IgG4 hinge domain.  Data are means ±SD from 
duplicate wells.   
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Figure 7: BBIR T cells fail to recognize TEM1 when expressed on the cell surface. 
(a) A schematic diagram of a BBIR T cell.  Briefy, T cells are transduced with a 
streptavidin-based BBIR that confers specificity to the T cells for biotionylated 
substrates.  Biotinylated antibodies are used to stain the surface of target tumor cells, 
which will then be recognized by the BBIR T cells.  (Used with permission – K. 
Urbanska) (b) Biotinylation of three antibodies against TEM1 and their ability to stain 
TEM1-positive endothelial targets.  MS1 or MS1TEM1 cells were stained with the listed 
antibodies before being split for (b) staining verification by flow cytometry or (c) co-
culture with BBIR T cells.  Cells stained for flow cytometry were washed and stained 
with a streptavidin-APC secondary before analysis by flow cytometry.  (c) IFN-γ 
production by BBIR T cells after co-culture with labeled endothelial targets.  Overnight 
co-cultures were performed with T cells and target cells at an E:T ratio of 5:1.  IFN-γ 
ELISAs were performed on the collected supernatants.  Representative experiment from a 
single donor shown.  Data are means ±SD from duplicate wells.   
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Figure 8: Design and characterization of an anti-PSMA CAR.  (a) Lentiviral cassette 
design for the J591-based CAR constructs: Pζ, P28ζ, PBBζ, P28BBζ and the FR28BBζ 
specificity control.  (b) Schematic representation of the P28BBζ CAR.  (c) 
Representative transduction efficiencies, as measured by eGFP reporter, for the CAR 
constructs in primary human T cells.  Closed histograms depict untransduced cells; open 
histograms depict transduced T cells.  (d) Overlay of histograms comparing the 
proliferative capacity of the T cells groups 5 days after co-culture with HMEC-1PSMA.   
(e) Quantitative comparison of proliferation between CAR constructs harboring the 
different signaling domains.  The geometric mean fluorescence intensity of Cellvue® 
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Claret staining was measured for the CAR-positive T cells after 5 days in co-culture with 
either HMEC-1 or HMEC-1PSMA (E:T = 2:1).  To normalize across multiple donors, the 
MFI of CellVue® staining on CAR+ T cells after co-culture with HMEC-1PSMA was 
divided by the MFI of the CAR+ T cells after co-culture with the HMEC-1.  *P < 0.05; 
data are means ±SEM from three independent donors.  (f) Cytolytic activity of the 
various T cells after 18 h co-culture with HMEC-1 or HMEC-1PSMA.  Lysis was measured 
via luciferase assay (specific lysis = 100 – (luciferase signal treated / luciferase signal 
untreated × 100)).  Data are means ±SD from triplicate cultures.  
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Figure 9: Anti-PSMA CAR surface expression correlates with eGFP reporter 
expression. (a) Surface staining of untransduced and P28BBζ T cells using an APC-
conjugated goat anti-mouse F(ab’)2 fragment.   
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Figure 10: Bcl-xL induction in response to CAR T cell activation. (a) Expression of 
Bcl-xL in T cells five days after co-culture with HMEC-1 or HMEC-1PSMA endothelial 
targets (E:T = 2:1).  Representative donor shown.  (b) Quantification of Bcl-xL induction 
in T cells bearing the various CAR constructs.  T cells were stained for Bcl-xL five days 
after co-culture with HMEC-1 or HMEC-1PSMA, and the geometric mean fluorescence 
intensity was measured for the CAR-positive cells.  Results reported as fold induction of 
HMEC-1PSMA/HMEC-1.  Data are means ±SEM from four independent donors.  
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Figure 11: P28BBζ T cells recognize and eliminate PSMA-positive endothelial cells 
in vitro.  (a) Human PSMA expression on native (top row) and engineered (bottom row) 
endothelial cell lines.  PSMA was detected by humanized J591 Ab (open histogram) and 
compared with human IgG control (closed histogram).  (b) IFN-γ production by P28BBζ 
T cells after co-culture with endothelial targets (E:T = 3:1).  Culture supernatants were 
collected at 18 h and IFN-γ was measured by ELISA.  Representative donor shown; data 
are means ±SD of triplicate cultures.  (c) Cytolytic activity of P28BBζ T cells after 18 h 
co-culture with endothelial cell targets.  Cell lysis measured by chromium release.  
Representative donor shown; data are means ±SD of triplicate cultures.  
  
a b
c HMEC-1
Sp
ec
ifi
c 
ly
si
s 
(%
)
10
 to
 1
3 t
o 1
 
1 t
o 1
0
20
40
60
80
100
HMEC-1PSMA
10
 to
 1
3 t
o 1
 
1 t
o 1
0
20
40
60
80
100
E:T Ratio
Sp
ec
ifi
c 
ly
si
s 
(%
)
MS1
10
 to
 1
3 t
o 1
 
1 t
o 1
0
20
40
60
80
100
MS1PSMA
E:T Ratio
10
 to
 1
3 t
o 1
 
1 t
o 1
0
20
40
60
80
100
H5V
10
 to
 1
3 t
o 1
 
1 t
o 1
0
20
40
60
80
100
H5V
E:T Ratio
10
 to
 1
3 t
o 1
 
1 t
o 1
0
20
40
60
80
100
PSMA
IFN-  production after co-culture
IF
N
-
 (
g/
m
L)
T c
ell
s A
lon
e
HM
EC
-1
MS
1
H5
V
HM
EC
-1
PS
MA
MS
1P
SM
A
H5
V
PS
MA
0
2000
4000
6000
8000
10000
P28BB
FR28BB
FR28BB
P28BB
PSMA expression
HMEC-1PSMA
MS1 H5V
0 102 103 104 105
APC-A
0
Co
un
t
0 102 103 104 105
APC-A
0
Co
un
t
MS1PSMA
0 102 103 104 105
APC-A
0
Co
un
t
H5VPSMA
Human Murine
0 102 103 104 105
Comp-APC-A
0
20
40
60
80
100
%
 o
f M
ax
Sample Name
Specimen_001_HMEC-1 PSMA J59...
Specimen_001_HMEC-1 PSMA Isot...
0 102 103 104 105
Comp-APC-A
0
20
40
60
80
100
%
 o
f M
ax
Sample Name
Specimen_001_HMEC-1 J591.fcs
Specimen_001_HMEC-1 Isotyp...
0 102 103 104 105
APC-A
0
Co
un
t
HMEC-1
Isotype J591/anti-human APC
92 
 
Figure 12: PSMA is expressed on the vasculature of primary and metastatic cancer. 
(a) Representative staining for PSMA on primary and metastatic ovarian tumors.  Top 
row: PSMA staining alone (brown).  Bottom row: Dual staining for PSMA (red) and the 
endothelium (CD34, brown).  Original magnification, 200×; scale bar, 50 µm. (b) A heat 
map showing the presence or absence of PSMA on the vasculature of tumors taken from 
subjects with resected ovarian cancer (n = 15).  (c) Representative tumor core staining for 
both PSMA (red) and CD34 (brown).  Black arrows indicate CD34+ vessels that are 
negative for PSMA expression, whereas the red arrows indicate dual-positive 
(CD34+PSMA+) vessels.  (d) Level of PSMA expression on tumor endothelial cells 
(CD45–CD31+) from three subjects with gynecological cancer.  Tumor endothelial cells 
were collected by CD45 depletion followed by CD31 enrichment.  PSMA was detected 
by humanized J591 Ab (open histogram) and compared with human IgG control (closed 
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histogram).  (e) The percentage of PSMA-positive CD45–CD31+ endothelial cells 
remaining after overnight co-culture with CAR T cells (E:T = 1:1). Percentage = treated / 
untreated × 100.  (f) IFN-γ production by P28BBζ T cells after co-culture with CD31 
enriched or depleted targets (E:T = 1:1).  Culture supernatants were collected at 18 h and 
IFN-γ was measured by ELISA. 
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Figure 13: PSMA expression on tumor cells. (a) PSMA and folate receptor expression 
on CD45 and CD31 depleted tumor digests from three women with gynecological cancer 
(patient #1913, 1965, and 1797).  Cell suspensions were stained for CD45, CD31, PSMA 
and folate receptor.  Dot plots show PSMA and folate receptor expression on the CD45–
CD31– gated populations.  PSMA expression was detected by humanized J591 Ab; folate 
receptor was detected using a commercially available Ab. 
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Figure 14: P28BBζ CAR T cells target human tumor vasculature expressing PSMA 
in vitro.  (a) Antigen-specific destruction of HMEC-1PSMA microvessels after 48 h co-
culture with P28BBζ T cells.  HMEC-1 or HMEC-1PSMA endothelial cells (red) were 
seeded atop a Matrigel basement membrane and allowed to form microvessels for 8 h 
prior to co-culture with CAR-bearing T cells (green)(E:T = 3:1).  Images were taken at 0, 
24, and 48 h.   Original magnification, 40×; scale bar, 1 mm.  (b) Immunofluorescence 
images of the HMEC-1PSMA endothelial cells at initiation (0 h) and termination (48 h) of 
co-culture with the P28BBζ T cells. Original magnification, 100×; scale bar, 500 µm.   
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Figure 15: P28BBζ CAR T cells target human tumor vasculature expressing PSMA 
in vivo.  (a) Experimental design for the HMEC-1 pilot study.  Mice were injected s.c. on 
each flank with 1.0×106 HMEC-1 (left flank) and 1.0×106 HMEC-1PSMA (right flank) 
endothelial cells.  T cells were administered concurrently via i.v. injection.  Treated mice 
received 5.0×106 CAR-positive T cells.  (b) Representative dot plots from treated or 
control mice showing human CD45 and CAR (eGFP) expression.  Matrigel plugs were 
retrieved upon sacrifice (11 d) and were digested with dispase and DNase to yield a 
single cell suspension.  Cells were subsequently stained for human CD45 and analyzed 
for eGFP expression using a flow cytometer.  (c) CAR T cells as a percentage of the cells 
isolated from the Matrigel plugs.  n = 2 mice in the FR28BBζ and P28BBζ; n = 1 mouse 
in the untreated (PBS) group.  Data are means ±SEM.  (d) CAR T cells as a percentage of 
total splenocytes.  Spleens were isolated from mice upon sacrifice, mechanically 
disrupted, and analyzed for the presence of CAR T cells (eGFP).  n = 2 mice in the 
FR28BBζ and P28BBζ; n = 1 mouse in the untreated (PBS) group.  Data are means 
±SEM.   
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Figure 16: P28BBζ CAR T cells eliminate PSMA+ hemangiomas. (a) Tumor injection 
schematic and experimental design for the MS1 hemangioma study.  Mice were injected 
s.c. on each flank with 1.0×107 MS1 (left flank) and 1.0×107 MS1PSMA (right flank) 
endothelial cells.  Hemangiomas were allowed to develop for 24 days prior to i.v. 
injection of T cells. (b) Tumor progression, as measured by luciferase luminescence, in 
mice receiving PBS, FR28BBζ, or P28BBζ T cells.  Mice were given a single injection of 
5.0×106 CAR-positive T cells (arrows) 24 days after inoculation with tumor.  n = 5 mice 
per group; data are means ±SEM.  *P < 0.05, as determined by two-tailed Student’s t test, 
for the P28BBζ treated group when compared to the FR28BBζ control group at the 
indicated time points.  (c) Representative hemangiomas at the time of sacrifice (day 53).    
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Figure 17: P28BBζ T cell mediated regression of large PSMA+ hemangiomas.  (a) 
Experimental design for the MS1 hemangioma study.  Mice were injected s.c. on each 
flank with 1.5×107 MS1 (left flank) and 1.5×107 MS1PSMA (right flank) endothelial cells.   
The MS1 and MS1PSMA endothelial cells were engineered to express firefly luciferase.  
Large palpable hemangiomas were allowed to form prior to i.v. injection of T cells. (b) 
Tumor progression, as measured by luciferase luminescence, in mice receiving PBS, 
FR28BBζ, or P28BBζ T cells. Mice were given a single injection of 1.0×107 CAR-
positive T cells (arrows) 84 days after inoculation with tumor.  Hemangioma progression 
was monitored longitudinally via luciferase luminescence (left column) and caliper 
measurement (volume, right column).  n = 5 mice per group; data are means ±SEM.  *P 
< 0.05, as determined by two-tailed Student’s t test, for the P28BBζ treated group when 
compared to the FR28BBζ control group at the indicated time points.  (c) Representative 
hemangiomas at the time of sacrifice (day 106).  
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Figure 18: P28BBζ CAR T cells eliminate PSMA+ hemangiosarcomas.  (a) 
Experimental design for the H5V hemangiosarcoma tumor study.  Mice were injected i.v. 
with 5.0×105 H5VPSMA endothelial cells.  Lung tumors were allowed to engraft for 3 
weeks prior to administration of T cells.  (b) Tumor progression, as measured by 
luciferase luminescence, in mice receiving PBS, FR28BBζ, or P28BBζ T cells.  Mice 
were given three injections of 5.0×106 CAR-positive T cells beginning 21 days after 
tumor inoculation (arrows).  n = 5 mice per group; data are means ±SEM.  *P < 0.05, as 
determined by two-tailed Student’s t test, for the P28BBζ treated group when compared 
to the FR28BBζ control group at the indicated time points.  (c) Survival curve for mice 
with H5VPSMA tumors.  P28BBζ treated mice were sacrificed on day 108.  P = 0.002, as 
determined by log-ranked (Mantel-Cox) test.  n = 5 mice per group.  (d) Tumor 
luminescence in representative mice before (day 20) and after T cell treatment (day 45). 
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Figure 19: The MS1/ID8VEGF tumor model closely mimics normal tumor physiology. 
(a) Tumor injection schematic and experimental design for the MS1/ID8VEGF 
characterization study.  Mice were given a single s.c. injection of 1.0×106 ID8VEGF tumor 
cells either alone or with 1.5×107 MS1 or 1.5×107 MS1PSMA endothelial cells and 
monitored for 41 days.  (b) The percentage of MS1PSMA derived endothelial cells 
(CD31+) in ID8 tumors at time of sacrifice.  PSMA was detected by humanized J591 Ab.  
*P < 0.0001, as determined by two-tailed Student’s t test.  n = 4 mice per group; data are 
means ±SEM.  (c) Representative staining for CD31 (green) and PSMA (blue) from an 
MS1PSMA/ID8VEGF tumor (d 41).  Original magnification, 200×; scale bar, 100 µm. (d) 
The portion of CD31+ endothelial cells present in tumor digests reported as a percentage 
of the total number of live cells collected. n = 4 mice per group; data are means ±SEM.  
(e) Tumor progression in mice harboring ID8VEGF, MS1/ID8VEGF, or MS1PSMA/ID8VEGF 
tumors.  Tumor volumes were calculated via caliper measurement.  n = 4 mice per group; 
data are means ±SEM. 
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Figure 20: The contribution of endothelial cells to tumor cells remains constant 
during tumor development. (a) Representative images taken from the same mouse on 
day 17 and 41 showing eGFP radiance and firefly luminescence.  (b,d) Correlation of 
endothelial cell signal (firefly luciferase, luminescence) with tumor signal (eGFP, radiant 
efficiency).  Linear regression analysis was performed and the slope of best fit is shown 
(solid lines) for individual mice with either MS1/ID8VEGF (f) or MS1PSMA/ID8VEGF (g) 
tumors.  (c,e) Statistical analysis describing the correlation of luminescence and radiant 
efficiency in mice with MS1/ID8VEGF (h) and MS1PSMA/ID8VEGF (i) tumors.  
Measurements were taken at time points between 17–41 days after inoculation with 
tumor and the luciferase and radiant efficiency measurements were plotted against one 
another (n = 7).  Pearson correlation coefficients were calculated for each mouse (r).   
Significance evaluated by two-tailed test (P).  
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Figure 21: CAR T cells ablate PSMA+ vasculature in MS1/ID8 solid tumors. (a) 
Experimental design for the MS1/ID8 tumor study.  6.7×105 ID8 tumor cells were mixed 
with either 1.0×107 MS1 (left flank) or 1.0×107 MS1PSMA (right flank) endothelial cells 
and injected s.c. on the opposite flanks of each mouse.  Tumors were allowed to engraft 
for 81 days before T cell administration.  (b) The persistence of the MS1 and MS1PSMA 
endothelial cells after treatment with PBS, FR28BBζ, or P28BBζ T cells.  Mice were 
given a single injection of 1.0×107 CAR-positive T cells 81 days after inoculation with 
tumor.  The presence (or absence) of the MS1 and MS1PSMA endothelial cells was 
monitored via luciferase luminescence and is reported as fold change over the values 
taken immediately prior to T cell administration on day 81.  n = 5 mice per group; data 
are means ±SEM.  *P < 0.05, as determined by two-tailed Student’s t test, for the 
P28BBζ treated group when compared to the FR28BBζ control group at the indicated 
time points. 
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Figure 22: CAR T cells ablate PSMA+ vasculature in MS1/ID8VEGF solid tumors. (a) 
Experimental design for the MS1/ID8VEGF tumor study.  6.7×105 ID8VEGF tumor cells 
were mixed with either 1.0×107 MS1 (left flank) or 1.0×107 MS1PSMA (right flank) 
endothelial cells and injected s.c. on the opposite flanks of each mouse.  Tumors were 
allowed to engraft for 25 days before treatment with CAR T cells.  (b) The persistence of 
the MS1 and MS1PSMA endothelial cells after treatment with PBS, FR28BBζ, or P28BBζ 
T cells.  Mice were given three injections of 5.0×106 CAR-positive T cells beginning 25 
days after tumor inoculation (arrows).   The presence (or absence) of the MS1 and 
MS1PSMA endothelial cells was monitored via luciferase luminescence. n = 5 mice per 
group; data are means ±SEM.  *P < 0.05, as determined by two-tailed Student’s t test, for 
the P28BBζ treated group when compared to the FR28BBζ control group at the indicated 
time points.  (c) The percentage of PSMA positive tumor endothelial cells (CD45–
CD31+) remaining after T cell administration to mice harboring MS1/ID8VEGF and 
MS1PSMA/ID8VEGF tumors.  PSMA was detected by humanized J591 Ab. n = 5 mice in the 
PBS and FR28BBζ groups; n = 2 mice in P28BBζ group.  Data are means ±SEM.  
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Figure 23: Anti-vascular CAR T cells cause tumor regression of MS1/ID8 solid 
tumors. (a) Tumor progression in the MS1/ID8 and MS1PSMA/ID8 tumors (Figure 21a) 
after treatment with PBS, FR28BBζ, or P28BBζ T cells.  Mice were given a single 
injection of 1.0×107 CAR-positive T cells 81 days after inoculation with tumor.  Tumor 
volumes were calculated via caliper measurement and are reported as fold change over 
values taken immediately prior to T cell administration on day 81.  n = 5 mice per group; 
data are means ±SEM.  *P < 0.05, as determined by two-tailed Student’s t test, for the 
P28BBζ treated group when compared to the FR28BBζ control group at the indicated 
time points.   
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Figure 24: Comparison of single vs. multiple injections of P28BBζ T cells. (a) 
Experimental design for the comparative dosing study.  6.7×105 ID8VEGF tumor cells were 
mixed with either 1.0×107 MS1 (left flank) or 1.0×107 MS1PSMA (right flank) endothelial 
cells and injected s.c. on opposite flanks of the same mice.  Mice received either a single 
dose of 1.0×107 CAR-positive T cells (1FR28BBζ and 1P28BBζ, blue arrows) or a series 
of three injections of 5.0×107 CAR-positive T cells (P28BBζ, black arrows).  Experiment 
was run concurrently with Figure 22a.  Luminescence values for the P28BBζ group are 
identical to those shown in Figure 22b.  (b) Tumor progression in mice receiving 
P28BBζ, 1FR28BBζ, or 1P28BBζ T cells.  The presence (or absence) of endothelial cells 
was monitored via luciferase luminescence (left column).  Tumor volumes (right column) 
were calculated via caliper measurement.  n = 5 mice in the P28BBζ and 1P28BBζ 
groups; n = 4 mice in 1FR28BBζ group.  Data are means ±SEM.  *P < 0.05, as 
determined by two-tailed Student’s t test, for the 1P28BBζ treated group when compared 
to the 1FR28BBζ control group at the indicated time points.  
a MS1/ID8VEGF
Injection
T cell 
Injections Sacrifice
Day 0 Day 4525, 28, 31
Endothelial cell luminescence  Tumor volumeb
0 10 20 30 40 50
0
1 107
2 107
3 107
Lu
m
in
es
ce
nc
e
(p
/s
/c
m
/s
r)
0 10 20 30 40 50
0
1 107
2 107
3 107
Lu
m
in
es
ce
nc
e
(p
/s
/c
m
/s
r)
0 10 20 30 40 50
0
200
400
600
800
Vo
lu
m
e 
(m
m
3 )
P28BB
FR28BB  
P28BB  
0 10 20 30 40 50
0
200
400
600
800
Vo
lu
m
e 
(m
m
3 )
Time (d) Time (d)
Time (d) Time (d)
MS1 flank MS1/ID8VEGF
flank
MS1PSMA flank MS1PSMA/ID8VEGF
flank
*
* P < 0.05
* *
1
1
106 
 
Figure 25: CAR T cells induce secondary loss of tumor cells and regression of solid 
tumors. (a) Experimental design for the MS1/ID8VEGF tumor study.  6.7×105 ID8VEGF 
tumor cells were mixed with either 1.0×107 MS1 (left flank) or 1.0×107 MS1PSMA (right 
flank) endothelial cells and injected s.c. on opposite flanks of the same mice.  Tumors 
were allowed to engraft for 22 days before T cell administration.  (b) Tumor progression 
in mice receiving PBS, FR28BBζ, or P28BBζ T cells.  Mice were given three injections 
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of 5.0×106 CAR-positive T cells beginning 22 days after tumor inoculation (arrows).  The 
impact of T cell administration on the ID8VEGF tumor cells was measured via luciferase 
luminescence (left column) and tumor volumes were calculated using caliper 
measurements (right column).  n = 5 mice per group; data are means ±SEM.  *P < 0.05, 
as determined by two-tailed Student’s t test, for the P28BBζ treated group when 
compared to the FR28BBζ control group at the indicated time points.  (c) The fold 
change in ID8VEGF tumor cell luminescence from the MS1/ID8VEGF and MS1PSMA/ID8VEGF 
tumors in mice receiving P28BBζ T cells.  Luminescence measurements were normalized 
to those made prior to treatment (day 21).  P values were determined by two-tailed 
Student’s t test and reflect the significance of changes between day 24 and day 28.  n = 5.  
(d) P28BBζ T cells do not elicit bystander killing of ID8VEGF when cultured in the 
presence of MS1PSMA.  MS1PSMA cells were titrated into wells with ID8VEGF tumor cells 
and T cells at the described ratios and were cultured for 18 h.  Lysis was measured via 
luciferase assay (specific lysis = 100 – (luciferase signal treated / luciferase signal 
untreated × 100)).  Data are means ±SD from triplicate cultures. 
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Figure 26: PSMA expression in normal tissues.  Representative staining, using the 3E6 
antibody, for PSMA on normal tissues. PSMA staining alone (brown). Original 
magnification, 200×; scale bar, 200 µm. 
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Figure 27: PSMA exists as multiple isoforms.  In the normal prostate, PSMA is 
expressed predominantly as PSM’.  Although the PSM’ isoform retains its catalytic 
domain, it is unclear whether it functions as a hydrolase within the cytosol.103  In prostate 
cancer, as well as on the neovasculature of solid tumors, full length PSMA isoform 1 is 
highly expressed.  The exclusion of exon 18 from PSMA isoform 2 is expected leave the 
enzyme catalytically inactive, as this exon contains the dimerization domain required for 
catalytic function of the protein.104,105 The functional relevance of this isoform, as well as 
the remaining variants, has yet to be determined.     
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Figure 28: J591-based CAR T cells exclusively recognize PSMA isoform 1. IFN-γ 
production by Pζ T cells after co-culture with endothelial targets (E:T = 5:1).  Culture 
supernatants were collected at 18 h and IFN-γ was measured by ELISA.  Representative 
donor shown; data are means ±SD of triplicate cultures. 
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Figure 29: Validation of PCR primers used to distinguish PSMA isoform 1 and 2. 
(a) Schematic representation of PCR primers designed to distinguish PSMA isoform 1 
from PSMA isoform 2.  The forward primer (1) was designed to sit within the shared 
transmembrane domain between the two isoforms, thereby excluding the cytosolic 
variants of the protein.  The reverse primer (2) recognizes a sequence on exon 19, which 
is shared between the two isoforms.  PCR products of 2016 bp and 1922 bp are expected 
for PSMA isoforms 1 and 2, respectively.  (b) RT-PCR analysis for PSMA isoforms 1 
and 2 performed on cDNA samples collected from endothelial cells engineered to express 
PSMA (HMEC-1) or a prostate cancer cell line control, LNCaP.  Plasmids containing 
PSMA isoform 1 and/or 2 were also amplified as controls.   
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Figure 30: 18s internal loading controls for cDNA created from normal tissues.  (a) 
PCR was performed on cDNA collected from cell lines and normal tissues using primers 
specific for the 18s ribosomal RNA. Dilutions were made from the resulting product and 
gel electrophoresis was conducted to confirm similar concentrations of starting material 
were used across all samples.  The cDNA was then used for PSMA isoform analysis 
(Figure 31).    
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Figure 31: RT-PCR analysis of the membrane-bound PSMA isoforms from normal 
tissues. (a) Schematic representation of PCR primers designed to distinguish PSMA 
isoform 1 from PSMA isoform 2. (b) Polyacrylamide gel electrophoresis of PCR 
products generated from a panel of normal tissues.  Plasmid DNA containing PSMA 
isoform 1 and/or 2 were also amplified, and serve as controls. 
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